Tricyclic amide compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
By developing a pharmaceutical composition of triangular cyclic amide compound, the defects in the prior art that cannot effectively inhibit PRMT5 are solved, effective inhibition and blockade of MTAP-deleted tumor cells are achieved, and new methods for treating various cancers are provided.
Patent Information
- Application Number
- PCT/CN2024/082382
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-04
- Filing Date
- 2024-03-19
- Publication Date
- 2024-11-21
AI Technical Summary
The existing PRMT5 inhibitors have not been launched yet and cannot effectively inhibit tumor cells deficient in MTAP, leading to malignant tumor progression. It is necessary to develop new, efficient and low-toxic PRMT5 inhibitors.
A triaxial cyclic amide compound has been developed to inhibit MTAP-deleted tumor cells through its pharmaceutical composition and possess good pharmacokinetic properties for the prevention or treatment of diseases associated with PRMT5 activity.
This compound effectively inhibits PRMT5 activity, blocks the methylation function of tumor cells, significantly improves the killing efficacy of MTAP-deleted tumor cells, and provides a new potential means to treat cancers such as breast, pancreas, and lungs.
Smart Images

Figure CN2024082382_21112024_PF_FP_ABST
Abstract
Description
Tricyclic amide compound, pharmaceutical composition containing the same, preparation method and use thereof Technical Field
[0001] The present invention relates to tricyclic amide compounds, pharmaceutical compositions containing the same, methods for preparing the same, and their use in preventing or treating diseases or conditions associated with PRMT5 activity. Background Art
[0002] Arginine N-terminal methyltransferase 5 (PRMT5), a member of the PRMT family, is a key component of post-translational histone modification (arginine methylation) in eukaryotic cells and an epigenetic target. PRMT5 is widely present in the nucleus and cytoplasm of human cells, including tissues such as the heart, muscle, and testis. PRMT5 catalyzes the transfer of a methyl group from a SAM to an arginine guanidinium group on histones or non-histone proteins, generating monomethylated arginine (MMA) and symmetric dimethylarginine (sDMA) products, which affect multiple target genes and signaling pathways. PRMT5 also associates with methylosome protein 50 (MEP50) to form a heterooctameric PRMT50 / MEP50 complex, enhancing PRMT5 methyltransferase activity (Stephen Antonysamy et al., Crystal structure of the human PRMT5: MEP50 complex, PNAS, 2012, vol. 109, no. 44, 17960–17965). PRMT5 is involved in regulating gene expression (activation / repression), RNA metabolism, cell cycle and protein function.
[0003] PRMT5 can methylate and modify a variety of substrates to alter their biological activity or affect the transcriptional regulation of genes in related pathways. In breast cancer, PRMT5 participates in FOXP1 transcription, upregulates FOXP1 expression, and promotes the self-renewal and tumorigenicity of breast cancer stem cells. In pancreatic cancer, PRMT5 can bind to the promoter region of the E3 ubiquitin ligase FBW7, inhibit FBW7 expression, enhance MYC stability, and promote tumor malignant progression. In lung cancer cells, PRMT5 can inhibit the transcription of the miR-99 family, increase FGFR3 expression, and activate the Erk1 / 2 and Ak pathways, leading to cell growth and metastasis.
[0004] MTAP is the gene encoding methylthioadenosine phosphorylase, located on chromosome 9p21, close to the tumor suppressor gene CDKN2A (which often undergoes homozygous deletion). Therefore, MTAP is often co-deleted with CDKN2A in tumors (Marjon K, Kalev P, Marks K., Cancer Dependencies: PRMT5 and MAT2A in MTAP / p16-Deleted Cancers, Annual Review of Cancer Biology, 2021, 5(1): 371-390.). Approximately 15% of solid tumors suffer from MTAP deletion.
[0005] PRMT5 has two cofactors: an activating cofactor (SAM) and an inhibitory cofactor (MTA; 5'-methylthioadenosine). In normal cells, MTAP is responsible for converting MTA to Met (methionine), while PRMT5 is responsible for converting SAM to SAH (S-adenosyl-L-homocysteine). MTA is an endogenous competitive inhibitor of the PRMT5-SAM complex. In tumor cells, the loss of MTAP leads to the accumulation of MTA, partially inhibiting PRMT5 activity and making tumor cells more dependent on PRMT5. In these cases, inhibiting PRMT5 can further block the methylation function of PRMT5, leading to tumor cell death.
[0006] In summary, inhibition of PRMT5 exhibits synthetic lethality in the absence of MTAP. Currently, no PRMT5 inhibitors are available. Therefore, the development of novel, highly effective, and low-toxic PRMT5 inhibitors is needed to meet clinical needs.
[0007] Summary of the Invention
[0008] The present invention provides a tricyclic amide compound, which has a good inhibitory effect on MTAP-deficient tumor cells and has good pharmacokinetic properties.
[0009] One aspect of the present invention provides a compound of Formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof:
[0010] in:
[0011] Ring A is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aromatic rings and 5-10 membered heteroaromatic rings;
[0012] R is selected from:
[0013] X1 、X 2 、X 3 Each independently selected from CR 9 and N;
[0014] X 4 、X 5 are each independently selected from C and N;
[0015] X 6 、X 7 、X 8 Each independently selected from CR 1 and N;
[0016] is a single bond or multiple bonds;
[0017] R 1 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent;
[0018] R 2 For LR 2 ';
[0019] L is selected from a direct bond and -(CR 5 R 6 ) p -;
[0020] R 2 'Selected from hydrogen, deuterium, C 1-6 Alkyl, C 2-10 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R 12 、-OR 11 、-C(O)OR 11 、-C(O)R 12 and -C(O)NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, nitro, azido, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-10 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-10 Aryl, C 1-4 alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent;
[0021] R 3 Selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent;
[0022] R 4 Each occurrence is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, oxo, C 1-6 Alkyl, C 2-10 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、 -C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 5 R 6 、-C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R 5 )-C(O)R12 or, R 3 、R 4 The atoms to which it is connected form a 3-8 membered heterocyclic group, a 5-8 membered cycloalkyl group, a C 6-10 aromatic rings and 5-10 membered heteroaromatic rings;
[0023] R 5 and R 6 are independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-6 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent, or
[0024] R 5 and R 6 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent;
[0025] R 7 and R 8 are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-6 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent, or
[0026] R 7 and R 8 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent;
[0027] R 9 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 5 R 6 、-C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R 5 )-C(O)R 12 substituted by a substituent;
[0028] Each R 10 independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent;
[0029] Each R 11 independently selected from hydrogen, deuterium, C 1-6 Alkyl, C2-6 Alkenyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent;
[0030] Each R 12 independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent;
[0031] n is 0, 1, 2, or 3;
[0032] p is 1 or 2;
[0033] Each r is independently 0, 1 or 2.
[0034] One aspect of the present invention provides a compound of Formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof:
[0035] in:
[0036] Ring A is selected from C 6-10 aromatic rings and 5-10 membered heteroaromatic rings;
[0037] R is selected from:
[0038] R 1 are each independently selected from H, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl and C 3-6 Cycloalkyl;
[0039] X 1 、X 2 、X 3 Each independently selected from CR 9 and N;
[0040] R 2 For LR 2 ';
[0041] L is selected from a direct bond and -(CR 5 R 6 ) p -;
[0042] R 2 'Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 2-6 Heteroalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl and 5-10 membered heteroaryl, the alkyl, alkoxy, hydroxyalkyl, heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted with one or more halogen, -OH, -CN, -NR 7 R 8 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic group, C 6-10 aryl, 5-10 membered heteroaryl substituted;
[0043] R 3 Selected from H and C 1-4 alkyl;
[0044] R 4 is independently selected at each occurrence from H, -OH, halogen, -CN, -NR 7 R 8、-NHCOCH3、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, wherein the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted by one or more halogen, -CN, -NR 5 R 6 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 substituted by cycloalkoxy or 3-6 membered heterocyclic group; or, R 3 、R 4 The atoms to which it is connected form a 3-8 membered heterocyclic group, a 5-8 membered cycloalkyl group, a C 6-10 aromatic rings and 5-10 membered heteroaromatic rings;
[0045] R 5 and R 6 Each independently selected from H, C 1-4 Alkyl and C 3-8 Cycloalkyl;
[0046] R 7 and R 8 Each independently selected from H and C 1-4 alkyl;
[0047] R 9 are each independently selected from H, halogen, C 1-4 Alkyl and C 1-4 alkyl halide;
[0048] m is 0, 1, or 2;
[0049] n is 0, 1, 2, or 3;
[0050] p is 1 or 2.
[0051] Another aspect of the present invention provides a pharmaceutical composition comprising a preventively or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof and one or more pharmaceutically acceptable carriers.
[0052] Another aspect of the present invention provides use of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, or a pharmaceutical composition of the present invention in the preparation of a medicament for preventing or treating a disease or condition associated with PRMT5 activity.
[0053] Another aspect of the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, or a pharmaceutical composition of the present invention, for use in preventing or treating a disease or condition associated with PRMT5 activity.
[0054] Another aspect of the present invention provides a method for preventing or treating a disease or condition associated with PRMT5 activity, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, or a pharmaceutical composition of the present invention.
[0055] Another aspect of the present invention provides a process for preparing the compounds of formula I of the present invention.
[0056] definition
[0057] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art. References to technology used herein are intended to refer to technology commonly understood in the art, including variations of technology or substitutions of equivalent technology that would be apparent to those skilled in the art. While it is believed that the following terms are well understood by those skilled in the art, the following definitions are set forth to better explain the present invention.
[0058] The terms "comprising," "including," "having," "containing," or "involving," and other variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps, even though the additional unrecited elements or method steps are not necessarily present (i.e., these terms also encompass the terms "consisting essentially of" and "consisting of.").
[0059] As used herein, the term "alkyl" is defined as a linear or branched saturated aliphatic hydrocarbon. In some embodiments, the alkyl group has 1 to 12, such as 1 to 6, carbon atoms. For example, as used herein, the term "C 1-6 Alkyl" and "C 1-4"Alkyl" refers to a linear or branched group having 1 to 6 carbon atoms and 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl), which is optionally substituted by one or more (e.g., 1 to 3) suitable substituents such as halogen (in which case the group is referred to as "haloalkyl") (e.g., CH2F, CHF2, CF3, CCl3, C2F5, C2Cl5, CH2CF3, CH2Cl or -CH2CH2CF3, etc.). The term "C 1-4 "Alkyl" refers to a linear or branched aliphatic hydrocarbon chain of 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
[0060] As used herein, the term "heteroalkyl" refers to an alkyl group having one or more backbone atoms independently selected from atoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, or a combination thereof, in the backbone carbon atoms of the alkyl group. Numerical ranges (e.g., C 1-6 Assorted alkyl) refers to the number of carbons in the chain, which in this example includes 1-6 carbon atoms. For example, a -CH2OCH2CH3 group is referred to as a C3 assorted alkyl, and a -CH2OCH2CH2NHCH3 group is referred to as a C4 assorted alkyl. Connection to the rest of the molecule can be through heteroatoms or carbon atoms in the assorted alkyl chain.
[0061] As used herein, the term "haloalkyl" refers to an alkyl group substituted by one or more (such as 1 to 3) the same or different halogen atoms. 1-8 Halogenated alkyl, "C 1-6 Haloalkyl" and "C 1-4 The term "haloalkyl" refers to a haloalkyl group having 1 to 8 carbon atoms, 1 to 6 carbon atoms, and 1-4 carbon atoms, respectively, such as -CF3, -C2F5, -CHF2, -CH2F, -CH2CF3, -CH2Cl, or -CH2CH2CF3.
[0062] As used herein, the term "hydroxyalkyl" refers to a group in which a hydrogen atom in an alkyl group is replaced by one or more hydroxyl groups, for example, C 1-4 Hydroxyalkyl or C 1-3 Examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, -CH(OH)CH3, and the like.
[0063] As used herein, the term "alkoxy" refers to an -O-alkyl group, wherein the alkyl group is as described above. The alkoxy group herein may contain 1 to 12 carbon atoms, preferably C 1-8 Alkoxy, C 1-6 Alkoxy, C 1-4 Alkoxy or C 1-3Alkoxy. C 1-6 Representative examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy, and the like, wherein the alkoxy groups are optionally substituted with one or more (such as 1 to 3) identical or different substituents. For example, the term "haloalkoxy" refers to an alkoxy group wherein the hydrogen atoms are substituted with one or more (such as 1 to 3) identical or different halogen atoms.
[0064] As used herein, the term "paracyclic" or "fused ring" refers to a ring system formed by two or more cyclic structures that share two adjacent atoms.
[0065] As used herein, the term "spirocycle" refers to a ring system formed by two or more cyclic structures that share one ring atom with each other.
[0066] As used herein, the term "bridged ring" refers to a ring system formed by two or more cyclic structures sharing two atoms that are not directly connected to each other.
[0067] As used herein, the term "cycloalkyl" refers to a saturated or unsaturated non-aromatic monocyclic or polycyclic (such as bicyclic) hydrocarbon ring group, including but not limited to monocyclic alkyl (such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, etc.) and bicyclic alkyl, including spirocyclic, annular (condensed) or bridged ring systems (i.e., spirocyclic alkyl, annular (condensed) alkyl and bridged cycloalkyl, such as bicyclo [1.1.1] pentyl, bicyclo [2.2.1] heptyl, etc.). In the present invention, cycloalkyl is optionally substituted with one or more (such as 1 to 3) identical or different substituents. The carbon atoms on the cycloalkyl are optionally substituted with oxo (oxo) groups (i.e., forming C=O). The term "C 3-8 "Cycloalkyl" refers to a cycloalkyl group having 3 to 8 ring carbon atoms, such as C 3-6 Cycloalkyl, which may be a monocyclic alkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, or a bicyclic alkyl, such as C 5-8 Spiroalkyl, C 5-8 Bridged cycloalkyl, C 5-8 Condensed cycloalkyl, C 5-6 Spiroalkyl, C 5-6 Bridged cycloalkyl or C 5-6 Fused cycloalkyl.
[0068] As used herein, the term "cycloalkoxy" refers to -O-cycloalkyl, wherein cycloalkyl is as defined above. Representative examples of cycloalkoxy include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0069] As used herein, the term "heterocyclyl" or "heterocycle" refers to an aliphatic monocyclic or polycyclic (e.g., cyclic, spirocyclic or bridged) group having 2 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14) carbon atoms and one or more (e.g., 1, 2, 3 or 4) heteroatoms, including but not limited to oxygen atoms, nitrogen atoms and sulfur atoms, wherein the carbon atoms and heteroatoms on the heterocyclyl are optionally substituted with oxo groups (e.g., forming C=O, S(=O) or S(=O)2), or are optionally substituted with one or more (e.g., 1 to 3) independently selected from halogen and C 1-3 Alkyl is substituted by a substituent. For example, C 3-8 Heterocyclic groups refer to heterocyclic groups having 3 to 8 carbon atoms, such as C 3-6 Heterocyclic group.
[0070] The term "3-11 membered heterocyclyl" means a heterocyclyl group containing 3-11 ring atoms, including but not limited to a 4-10 membered heterocyclyl group, a 4-9 membered heterocyclyl group, a 4-8 membered heterocyclyl group, a 4-7 membered heterocyclyl group, a 5-6 membered heterocyclyl group, a 3-10 membered heterocyclyl group, a 3-8 membered heterocyclyl group, a 3-7 membered heterocyclyl group, a 4-7 membered nitrogen-containing heterocyclyl group, a 4-7 membered oxygen-containing heterocyclyl group, a 4-7 membered sulfur-containing heterocyclyl group, a 5-6 membered nitrogen-containing heterocyclyl group, a 5-6 membered oxygen-containing heterocyclyl group, a 5-6 membered sulfur-containing heterocyclyl group, and the like, wherein each of the "nitrogen-containing heterocyclyl group", "oxygen-containing heterocyclyl group" and "sulfur-containing heterocyclyl group" optionally further contains one or more other heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of 4-11 membered heterocyclic groups include, but are not limited to, oxiranyl, aziridinyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, pyrrolidonyl (e.g. ), imidazolidinyl, pyrazolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl.
[0071] In the present invention, the heterocyclic group may also include a parallel ring structure formed with a heterocyclic group or a cycloalkyl group. The connection point of the parallel ring structure with the other group may be on any heterocyclic group or cycloalkyl group. Therefore, the heterocyclic group of the present invention also includes (but is not limited to) heterocyclic and heterocyclic groups, heterocyclic and cycloalkyl groups, monoheterocyclic and monoheterocyclic groups, and monoheterocyclic and monocycloalkyl groups, such as 3-7 membered (mono) heterocyclic and 3-7 membered (mono) heterocyclic groups, 3-7 membered (mono) heterocyclic and (mono) cycloalkyl groups, 3-7 membered (mono) heterocyclic and C 4-6 (Mono)cycloalkyl, examples of which are not limited to pyrrolidinyl and cyclopropyl, cyclopentyl and aziridine, pyrrolidinyl and cyclobutyl, pyrrolidinyl and pyrrolidinyl, pyrrolidinyl and piperidinyl, pyrrolidinyl and piperazinyl, piperidinyl and morpholinyl,
[0072] In the present invention, the heterocyclic group also includes a bridged heterocyclic group and a spiro heterocyclic group.
[0073] As used herein, the term "bridged heterocycle" refers to a cyclic structure containing one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen atoms, nitrogen atoms, and / or sulfur atoms) formed by two saturated rings sharing two ring atoms that are not directly connected, including but not limited to 7-10 membered bridged heterocycles, 8-10 membered bridged heterocycles, 7-10 membered nitrogen-containing bridged heterocycles, 7-10 membered oxygen-containing bridged heterocycles, 7-10 membered sulfur-containing bridged heterocycles, etc., for example The “nitrogen-containing bridged heterocycle”, “oxygen-containing bridged heterocycle” and “sulfur-containing bridged heterocycle” optionally further contain one or more other heteroatoms independently selected from oxygen, nitrogen and sulfur.
[0074] As used herein, the term "spiroheterocycle" refers to a cyclic structure containing one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen atoms, nitrogen atoms, sulfur atoms) formed by two or more saturated rings sharing a ring atom, including but not limited to 5-10 membered spiroheterocycles, 6-10 membered spiroheterocycles, 6-10 membered nitrogen-containing spiroheterocycles, 6-10 membered oxygen-containing spiroheterocycles, 6-10 membered sulfur-containing spiroheterocycles, etc., for example The "nitrogen-containing spiroheterocycle", "oxygen-containing spiroheterocycle" and "sulfur-containing spiroheterocycle" optionally further contain one or more other heteroatoms independently selected from oxygen, nitrogen and sulfur. The term "6-10 membered nitrogen-containing spiroheterocyclyl" refers to a spiroheterocyclyl containing a total of 6-10 ring atoms, at least one of which is a nitrogen atom.
[0075] Examples of the group obtained by condensing a heterocyclic group with an aryl group include, but are not limited to:
[0076] As used herein, the term "aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic aromatic group having a conjugated π electron system. 6-12 "Aryl (aromatic ring)" means an aromatic group (aromatic ring) containing 6 to 12 carbon atoms, preferably C 6-10 Aryl (aromatic ring), preferably phenyl (phenyl ring) or naphthyl (naphthalene ring). Aryl is optionally substituted with one or more (such as 1 to 3) identical or different substituents (such as halogen, OH, CN, NO2, C1-C6 alkyl, etc.).
[0077] As used herein, the term "heteroaryl" or "heteroaromatic ring" refers to a monocyclic or polycyclic aromatic group containing one or more identical or different heteroatoms, including monocyclic heteroaryl groups and bicyclic or polycyclic ring systems containing at least one heteroaromatic ring (an aromatic ring system containing at least one heteroatom), which can have 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, for example 5, 6, 7, 8, 9 or 10 ring atoms. The heteroatom can be oxygen, nitrogen or sulfur. The carbon atoms and heteroatoms on the heteroaryl are optionally substituted with oxo groups (for example, to form C=O, S(=O) or S(=O)2).
[0078] As used herein, the term "5-10 membered heteroaryl" or "5-10 membered heteroaromatic ring" means a heteroaryl group (heteroaromatic ring) containing 5 to 10 (e.g., 5 to 6) ring atoms, including a 5-10 membered nitrogen-containing heteroaryl group, a 5-10 membered oxygen-containing heteroaryl group, a 5-10 membered sulfur-containing heteroaryl group, a 5-6 membered nitrogen-containing heteroaryl group, a 5-6 membered oxygen-containing heteroaryl group, a 5-6 membered sulfur-containing heteroaryl group, etc. The "nitrogen-containing heteroaryl group," "oxygen-containing heteroaryl group," and "sulfur-containing heteroaryl group" each optionally contain one or more other heteroatoms independently selected from oxygen, nitrogen, and sulfur. Examples include, but are not limited to, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, etc., or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., as well as 5-10 membered cyclic groups containing these groups.
[0079] As used herein, the term “C 3-10 "Heteroaryl" refers to a heteroaryl group containing 3 to 10 carbon atoms, such as C 5-10 Heteroaryl, C 5-6 Heteroaryl or C 3-5 Heteroaryl.
[0080] In the present invention, a heteroaryl group (e.g., a monoheteroaryl group) can share two adjacent atoms with an aryl group (e.g., a monocyclic aryl group, such as a phenyl group), a heterocyclic group (e.g., a monoheterocyclic group), a cycloalkyl group (e.g., a monocycloalkyl group) or another heteroaryl group (e.g., another monoheteroaryl group) to form a parallel ring structure, and the connection point can be on any heteroaryl ring or on other rings, including but not limited to (mono)heteroaryl and (mono)heteroaryl, (mono)heteroaryl and (mono)heterocyclic group and (mono)heteroaryl and (mono)cycloalkyl, such as a 5-6-membered (mono)heteroaryl and 5-6-membered (mono)heteroaryl, a 5-6-membered (mono)heteroarylphenyl group, a 5-6-membered (mono)heteroaryl and 5-6-membered (mono)heterocyclic group or a 5-6-membered (mono)heteroaryl and C 4-6(mono)cycloalkyl (e.g., 5-6 membered heteroarylcyclobutyl, 5-6 membered heteroarylcyclopentyl or 5-6 membered heteroarylcyclohexyl), examples of which are not limited to indolyl, isoindolyl, indazolyl, benzimidazole, quinolinyl, isoquinolinyl, wait.
[0081] As used herein, the term "halo" or "halogen" group is defined to include F, Cl, Br, or I.
[0082] The term "substituted" refers to one or more (e.g., one, two, three, or four) hydrogens on the designated atom being replaced by a selection from the designated group, provided that the normal atomic valence of the designated atom in the current situation is not exceeded and the replacement forms a stable compound. The combination of substituents and / or variables is permitted only when this combination forms a stable compound. The compounds of the present invention can also be substituted by suitable substituents in appropriate positions, and suitable substituents employ substituents described above in the application and those skilled in the art.
[0083] If a substituent is described as being "optionally substituted with one or more...", the substituent may be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of the listed substituents, one or more hydrogens on the carbon (to the extent of any hydrogens present) may be replaced, individually and / or collectively, with independently selected optional substituents. If a nitrogen of a substituent is described as being optionally substituted with one or more of the listed substituents, one or more hydrogens on the nitrogen (to the extent of any hydrogens present) may each be replaced with an independently selected optional substituent.
[0084] If substituents are described as being "independently selected" from a group, each substituent is selected independently of the other. Thus, each substituent may be the same as or different from another (other) substituent.
[0085] As used herein, the term "one or more" means 1 or more than 1, such as 2, 3, 4, 5 or 10, where reasonable.
[0086] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.
[0087] When a bond to a substituent is shown to pass through a bond connecting two atoms in a ring, then such substituent may be bonded to any ring atom in the substitutable ring.
[0088] The present invention also includes all pharmaceutically acceptable isotopically labeled compounds, which are identical to the compounds of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Examples of isotopes suitable for inclusion in the compounds of the present invention include, but are not limited to, isotopes of hydrogen (e.g., deuterium ( 2 H), tritium ( 3 H)); carbon isotopes (e.g. 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 36 Cl); isotopes of fluorine (e.g. 18 F); isotopes of iodine (such as 123 I and 125 I); isotopes of nitrogen (e.g. 13 N and 15 N); oxygen isotopes (e.g. 15 O. 17 O and 18 O); isotopes of phosphorus (such as 32 P); and sulfur isotopes (e.g. 35 S). Certain isotopically labeled compounds of the invention (e.g., those incorporating radioactive isotopes) are useful in drug and / or substrate tissue distribution studies (e.g., assays). The radioactive isotope tritium (i.e., 3 H) and carbon-14 (i.e. 14 C) are particularly useful for this purpose because they are easy to incorporate and easy to detect. 11 C. 18 F. 15 O and 13 N) substitution can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies. Isotopically labeled compounds of the present invention can be prepared by methods analogous to those described in the accompanying schemes and / or examples and preparations by using appropriate isotopically labeled reagents instead of the non-labeled reagents previously employed. Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent is isotopically substituted, for example, D2O, acetone-d6 or DMSO-d6.
[0089] The term "stereoisomer" refers to an isomer formed due to at least one asymmetric center. In a compound with one or more (e.g., one, two, three, or four) asymmetric centers, it can produce a racemic mixture, a single enantiomer, a diastereomeric mixture, and a separate diastereomer. Specific individual molecules can also exist as geometric isomers (cis / trans). Similarly, the compounds of the present invention can exist as mixtures of two or more structurally different forms in rapid equilibrium (commonly referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. For example, nitroso-oxime can exist in the following tautomeric form equilibrium in solution:
[0090] It is to be understood that the scope of this application encompasses all such isomers in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%) or mixtures thereof.
[0091] In this article, solid lines can be used Solid wedge or virtual wedge The chemical bonds of the compounds of the present invention are depicted. The use of solid lines to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers at that carbon atom are included (e.g., specific enantiomers, racemic mixtures, etc.). The use of solid or dashed wedges to depict bonds to asymmetric carbon atoms is intended to indicate that the indicated stereoisomers exist. When present in a racemic mixture, solid and dashed wedges are used to define relative stereochemistry, not absolute stereochemistry. Unless otherwise indicated, the compounds of the present invention are intended to exist as stereoisomers, including cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof. The compounds of the present invention may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereomeric pairs).
[0092] The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be single polymorphs or mixtures of more than one polymorph in any ratio.
[0093] A cocrystal refers to a drug active molecule and other physiologically acceptable acid, base, salt, or non-ionic compound molecules bound in the same crystal lattice by hydrogen bonds, π-π stacking, van der Waals forces, and other non-covalent bonds.
[0094] It should also be understood that certain compounds of the present invention may be used therapeutically in free form or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, N-oxides, metabolites, or prodrugs that, upon administration to a patient in need thereof, are capable of directly or indirectly providing a compound of the present invention or a metabolite or residue thereof. Therefore, when reference is made herein to a "compound of the present invention," such various derivative forms of the compound are also intended to be encompassed.
[0095] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof.
[0096] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof, such as hexafluorophosphate salts and meglumine salts. For a review of suitable salts, see Stahl and Wermuth, "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, 2002).
[0097] As used herein, the term "ester" refers to esters derived from the compounds of the general formulae herein, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release the compounds of the present invention in the form of free acid or alcohol). The compounds of the present invention themselves may also be esters.
[0098] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.
[0099] Those skilled in the art will appreciate that, because nitrogen requires available lone pairs of electrons to be oxidized to oxides, not all nitrogen-containing heterocycles can form N-oxides. Those skilled in the art will recognize nitrogen-containing heterocycles that can form N-oxides. Those skilled in the art will also recognize that tertiary amines can form N-oxides. The synthetic method for preparing the N-oxide of heterocycles and tertiary amines is well known to those skilled in the art, including but not limited to oxidizing heterocycles and tertiary amines with peroxyacids such as Peracetic Acid and Metachloroperbenzoic Acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate and dioxirane such as dimethyldioxirane. These methods for preparing N-oxides have been extensively described and reviewed in the literature, see for example: TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; AR Katritzky and AJ Boulton, Eds., Academic Press; and GWH Cheeseman and ESGWerstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, AR Katritzky and AJ Boulton, Eds., Academic Press.
[0100] Also included within the scope of the present invention are metabolites of the compounds of the invention, i.e., substances formed in vivo upon administration of the compounds of the invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc. of the administered compound. Thus, the present invention includes metabolites of the compounds of the invention, including compounds produced by contacting a compound of the invention with a mammal for a period of time sufficient to produce a metabolic product thereof.
[0101] The present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may themselves have little or no pharmacological activity and can be converted into compounds of the present invention having the desired activity by, for example, hydrolytic cleavage when administered to the body or thereon. Typically, such prodrugs will be functional group derivatives of the compounds that are readily converted into the desired therapeutically active compounds in vivo. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems", Volume 14, ACS Symposium Series (T. Higuchi and V. Stella). Prodrugs of the present invention can be prepared, for example, by replacing appropriate functional groups present in the compounds of the present invention with certain moieties known to those skilled in the art as "pro-moieties" (e.g., as described in "Design of Prodrugs", H. Bundgaard (Elsevier, 1985)).
[0102] The present invention also encompasses compounds of the present invention that contain protecting groups. During any process for preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved using conventional protecting groups, for example, those described in TW Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.
[0103] The term "about" means within ±10%, preferably within ±5%, more preferably within ±2% of the stated value. It should be noted that if there is a discrepancy between a described structure and the name of the structure, the described structure will be given greater weight.
[0104] Compound
[0105] In some embodiments, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer, or isotopically labeled compound thereof:
[0106] in:
[0107] Ring A is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aromatic rings and 5-10 membered heteroaromatic rings;
[0108] R is selected from:
[0109] X 1 、X 2 、X 3 Each independently selected from CR 9 and N;
[0110] X 4 、X 5 are each independently selected from C and N;
[0111] X 6 、X 7 、X 8 Each independently selected from CR 1 and N;
[0112] is a single bond or multiple bonds;
[0113] R 1 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7)-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent;
[0114] R 2 For LR 2 ';
[0115] L is selected from a direct bond and -(CR 5 R 6 ) p -;
[0116] R 2 'Selected from hydrogen, deuterium, C 1-6 Alkyl, C 2-10 Heteroalkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R 12 、-OR 11 、-C(O)OR 11 、-C(O)R 12 and -C(O)NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, nitro, azido, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-10 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-10 Aryl, C 1-4 alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent;
[0117] R 3 Selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent;
[0118] R 4 Each occurrence is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, oxo, C 1-6 Alkyl, C 2-10 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 5 R 6 、-C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R5 )-C(O)R 12 or, R 3 、R 4 The atoms to which it is connected form a 3-8 membered heterocyclic group, a 5-8 membered cycloalkyl group, a C 6-10 aromatic rings and 5-10 membered heteroaromatic rings;
[0119] R 5 and R 6 are independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-6 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent, or
[0120] R 5 and R 6 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent;
[0121] R 7 and R 8 are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-6 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent, or
[0122] R 7 and R 8 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent;
[0123] R 9 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 5 R 6 、-C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R 5 )-C(O)R 12 substituted by a substituent;
[0124] Each R 10 independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent;
[0125] Each R 11 independently selected from hydrogen, deuterium, C 1-6 Alkyl, C2-6 Alkenyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent;
[0126] Each R 12 independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent;
[0127] n is 0, 1, 2, or 3;
[0128] p is 1 or 2;
[0129] Each r is independently 0, 1 or 2.
[0130] In some embodiments, R 1 are each independently selected from deuterium, halogen, cyano, nitro, azido, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent.
[0131] In some embodiments, R 2 'Selected from C 2-6 Alkenyl, C 6-10 Aryl, -S(O) r R 12 、-C(O)OR 11 、-C(O)R 12 and -C(O)NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, nitro, azido, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-10 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-10 Aryl, C 1-4 alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) rR 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent.
[0132] In some embodiments, R 2 'Selected from C 2-6 Alkenyl, C 6-10 Aryl, -S(O) r R 12 、-C(O)OR 11 、-C(O)R 12 and -C(O)NR 7 R 8 The above groups are independently optionally further substituted with one or more groups selected from amino, nitro, azido, C 2-6 Alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-10 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-10 Aryl, C 1-4 Alkyl substituted 5-8 membered heteroaryl =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O)r R 10 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent.
[0133] In some embodiments, R 3 Selected from halogen, cyano, nitro, azido, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent.
[0134] In some embodiments, R 4 Each occurrence is independently selected from hydrogen, deuterium, nitro, azido, oxo, C 2-10 Heteroalkyl, C 2-6 Alkenyl, C 6-10 Aryl, -C 0-6 Alkyl-OS(O)2R 10 、-C0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 5 R 6 、-C 0-6 Alkyl-C(O)NR 5 R 6 and -C0-6 Alkyl-N(R 5 )-C(O)R 12 or, R 3 、R 4 The atoms to which it is connected form a 3-8 membered heterocyclic group, a 5-8 membered cycloalkyl group, a C 6-10 aromatic rings and 5-10 membered heteroaromatic rings.
[0135] In some embodiments, R 4 Each occurrence is independently selected from hydrogen, deuterium, nitro, azido, oxo, C 2-10 Heteroalkyl, C 2-6 Alkenyl, C 6-10 Aryl, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted by one or more groups selected from deuterium, cyano, nitro, azido, deuterium, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 5 R 6 、-C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R 5 )-C(O)R 12 Substituted by
[0136] In some embodiments, R 5 and R 6 are each independently selected from deuterium, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-6 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent, or
[0137] R 5 and R 6 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-6 Alkyl, C 2-6Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 The alkanoyl group is substituted with an alkanoyl substituent.
[0138] In some embodiments, R 7 and R 8 Each independently chooses C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-6 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent, or
[0139] R 7 and R 8 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 The alkanoyl group is substituted with an alkanoyl substituent.
[0140] In some embodiments, R 9 are independently selected from deuterium, cyano, nitro, azido, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 5 R 6 、-C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R 5 )-C(O)R 12 substituted by a substituent.
[0141] In some embodiments, R 9 are independently selected from deuterium, cyano, nitro, azido, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 7 R 8 、-C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more groups selected from deuterium, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 、-C 0-6 Alkyl-S(O) r R 10 、-C 0-6 Alkyl-OR 11 、-C 0-6 Alkyl-C(O)OR 11 、-C 0-6 Alkyl-C(O)SR 11 、-C 0-6 Alkyl-SC(O)R 12 、-C 0-6 Alkyl-C(O)R 12 、-C 0-6 Alkyl-OC(O)R 12 、-C 0-6 Alkyl-P(O)(R 12 )2. -C 0-6 Alkyl-NR 5 R 6 、-C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R5 )-C(O)R 12 substituted by a substituent.
[0142] In some embodiments, each R 10 independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, 5-10 membered heteroaryl and -NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent.
[0143] In some embodiments, each R 10 independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, 5-10 membered heteroaryl and -NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent.
[0144] In some embodiments, each R 11 independently selected from deuterium, C 2-6 Alkenyl, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent.
[0145] In some embodiments, each R 11 independently selected from deuterium, C 2-6 Alkenyl, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, hydroxyl, =O, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent.
[0146] In some embodiments, R is selected from:
[0147] Among them, R 1 、X 1 、X 2 、X 3 , m are as defined above.
[0148] In some embodiments, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer, or isotopically labeled compound thereof:
[0149] in:
[0150] Ring A is selected from C 6-10 aromatic rings and 5-10 membered heteroaromatic rings;
[0151] R is selected from:
[0152] R 1 are each independently selected from H, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl and C 3-6 Cycloalkyl;
[0153] X 1 、X 2 、X 3 Each independently selected from CR 9 and N;
[0154] R 2 For LR 2 ';
[0155] L is selected from a direct bond and -(CR 5 R 6 ) p -;
[0156] R 2 'Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 2-6 Heteroalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl and 5-10 membered heteroaryl, the alkyl, alkoxy, hydroxyalkyl, heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted with one or more halogen, -OH, -CN, -NR 7 R 8 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic group, C 6-10 aryl, 5-10 membered heteroaryl substituted;
[0157] R 3 Selected from H and C 1-4 alkyl;
[0158] R 4 is independently selected at each occurrence from H, -OH, halogen, -CN, -NR 7 R 8 、-NHCOCH3、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, said heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted by one or more halogen, CN, -NR 5 R 6 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 substituted by cycloalkoxy or 3-6 membered heterocyclic group; or, R 3 、R 4 The atoms to which it is connected form a 3-8 membered heterocyclic group, a 5-8 membered cycloalkyl group, a C 6-10 aromatic rings and 5-10 membered heteroaromatic rings;
[0159] R 5 and R 6 Each independently selected from H, C 1-4 Alkyl and C 3-8 Cycloalkyl;
[0160] R 7 and R 8 Each independently selected from H and C 1-4 alkyl;
[0161] R 9 are each independently selected from H, halogen, C 1-4 Alkyl and C 1-4 alkyl halide;
[0162] m is 0, 1, or 2;
[0163] n is 0, 1, 2, or 3;
[0164] p is 1 or 2.
[0165] In certain embodiments, the present invention provides compounds of formula I wherein ring A is selected from phenyl and pyridyl.
[0166] In certain embodiments, the present invention provides compounds of formula I, wherein R 1 Each independently selected from H and C 1-4 alkyl.
[0167] In certain embodiments, the present invention provides compounds of formula I, wherein R 1 are each independently selected from H and methyl.
[0168] In certain embodiments, the present invention provides compounds of formula I, wherein L is selected from a direct bond or -(CR 5 R 6 ) p -, p is 1.
[0169] In certain embodiments, the present invention provides compounds of formula I, wherein R 5 and R 6 Each independently selected from H and C 1-4 alkyl.
[0170] In certain embodiments, the present invention provides compounds of formula I, wherein R 5 and R 6 are each independently selected from H and methyl.
[0171] In certain embodiments, the present invention provides compounds of formula I wherein L is selected from a direct bond, -CH2-, and -CH(CH3)-.
[0172] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Heteroalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl and 5-10 membered heteroaryl, wherein the alkyl, alkoxy, heteroalkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 The alkyl radicals are substituted with cycloalkyl, 3-6 membered heterocyclyl, or 5-10 membered heteroaryl.
[0173] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Heteroalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl and 5-10 membered heteroaryl, wherein the alkyl, alkoxy, heteroalkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 The cycloalkyl group or the 3-6 membered heterocyclic group may be substituted.
[0174] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Independently selected from C 1-4 Alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl and 5-6 membered heteroaryl, wherein the alkyl, alkoxy, heteroalkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 The cycloalkyl group or the 3-6 membered heterocyclic group may be substituted.
[0175] In certain embodiments, the present invention provides compounds of formula I, wherein R2 'Independently selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, C 3-6 Cycloalkyl and 5-6 membered heteroaryl, wherein the alkyl, heteroalkyl, cycloalkyl, heteroaryl are optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 The cycloalkyl group or the 3-6 membered heterocyclic group may be substituted.
[0176] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Heteroalkyl, C 3-8 Cycloalkyl, C 3-8 Heterocyclic and C 5-10 Heteroaryl, the alkyl, alkoxy, heteroalkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-6 Heterocyclic group, C 5-10 Heteroaryl substitution.
[0177] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Heteroalkyl, C 3-8 Cycloalkyl, C 3-8 Heterocyclic and C 5-10 Heteroaryl, the alkyl, alkoxy, heteroalkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Heterocyclic substitution.
[0178] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Independently selected from C 1-4 Alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 3-6 Cycloalkyl, C 3-6 Heterocyclic and C 5-6Heteroaryl, the alkyl, alkoxy, heteroalkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Heterocyclic substitution.
[0179] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Independently selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, C 3-6 Cycloalkyl and C 5-6 Heteroaryl, the alkyl, heteroalkyl, cycloalkyl, heteroaryl are optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Heterocyclic substitution.
[0180] In certain embodiments, R 2 'Independently selected from methyl, pyrimidinyl, pyridinyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, Pyrazolyl and -C 1-4 Alkyl-OC 1-4 Alkyl, the methyl, pyrimidinyl, pyridyl, cyclopropyl, cyclobutyl, cyclopentyl, pyrazolyl are optionally replaced by C 1-4 Alkyl, halogen substituted.
[0181] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Independently selected from methyl, pyrimidinyl, pyridinyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, Pyrazolyl and -CH2-O-CH3, the methyl, pyrimidinyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, pyrazolyl are optionally substituted with methyl, ethyl, propyl, F, Cl, Br and I.
[0182] In certain embodiments, R 2 'Independently selected from methyl, pyrimidinyl, pyridinyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, Pyrazolyl and -CH2-O-CH3, the methyl, pyrimidinyl, pyridyl, cyclopropyl, cyclobutyl, cyclopentyl, pyrazolyl are optionally substituted by methyl or F.
[0183] In certain embodiments, the present invention provides compounds of formula I, wherein R 2 'Independently selected from methyl, pyrimidinyl, isopropyl, cyclopropyl, Pyrazolyl and -CH2-O-CH3, the methyl, cyclopropyl, pyrazolyl are optionally substituted by methyl.
[0184] In certain embodiments, the present invention provides compounds of formula I, wherein R 3 Selected from H and C 1-4 alkyl.
[0185] In certain embodiments, the present invention provides compounds of formula I, wherein R 3 Selected from H, methyl, ethyl, propyl and butyl.
[0186] In certain embodiments, the present invention provides compounds of formula I, wherein R 3 is selected from H and methyl.
[0187] In certain embodiments, the present invention provides compounds of formula I, wherein R 3 For H.
[0188] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 is independently selected at each occurrence from H, halogen, CN, -NR 7 R 8 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, 5-10 membered heteroaryl, wherein the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, heteroaryl are optionally substituted by one or more halogen, CN, -NR 5 R 6 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 substituted with cycloalkoxy or 3-6 membered heterocyclic group.
[0189] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 Each occurrence is independently selected from H, halogen, C 1-4 Halogenated alkyl, C 1-4 Halogenated alkoxy, 5-6 membered heteroaryl, the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, heteroaryl are optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Haloalkyl substitution.
[0190] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 Each occurrence is independently selected from H, halogen, C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy, 5-6 membered heteroaryl, said heteroaryl being optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Haloalkyl substitution.
[0191] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 Each occurrence is independently selected from C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy and 5-6 membered heteroaryl (eg pyrazolyl), which is optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Haloalkyl substitution.
[0192] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 Each occurrence is independently selected from C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy and
[0193] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 is independently selected at each occurrence from H, halogen, CN, -NR 7 R 8 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, C3-C8 heterocyclic group, C 5-10 Heteroaryl, the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, heteroaryl are optionally substituted by one or more halogen, CN, -NR 5 R 6 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 Cycloalkoxy, C 3-6 Heterocyclic substitution.
[0194] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 Each occurrence is independently selected from H, halogen, C1-4 Halogenated alkyl, C 1-4 Halogenated alkoxy, C 5-10 Heteroaryl, optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Haloalkyl substitution.
[0195] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 Each occurrence is independently selected from C 1-4 Haloalkyl and C 1-4 Halogenated alkoxy.
[0196] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 Each occurrence is independently selected from C 1-4 Halogenated alkyl.
[0197] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 is independently trifluoromethyl, trifluoromethoxy and
[0198] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 and independently at each occurrence trifluoromethyl and trifluoromethoxy.
[0199] In certain embodiments, the present invention provides compounds of formula I, wherein R 4 is independently trifluoromethyl at each occurrence.
[0200] In certain embodiments, the present invention provides compounds of formula I, wherein R 3 and R 4 The atoms to which it is connected together form a 5-6-membered heterocyclic group, such as a 5-membered oxygen-containing heterocyclic ring or a 6-membered oxygen-containing heterocyclic ring.
[0201] In certain embodiments, the present invention provides compounds of formula I, wherein R 3 and R 4 The atoms to which it is attached together form a 5-6 membered heterocyclic group, such as a 5-membered oxygen-containing heterocyclic ring.
[0202] In certain embodiments, the present invention provides compounds of formula I, wherein R 3 and R 4 The atoms to which it is attached together form the following group:
[0203] In certain embodiments, the present invention provides compounds of formula I, wherein R 7 and R 8 Each independently selected from H and C1-4 alkyl.
[0204] In certain embodiments, the present invention provides compounds of formula I, wherein R 7 and R 8 Each is independently selected from H, methyl, ethyl, propyl and butyl.
[0205] In certain embodiments, the present invention provides compounds of formula I, wherein X 1 、X 2 Each independently selected from CR 9 and N.
[0206] In certain embodiments, the present invention provides compounds of formula I, wherein X 1 and X 2 Each independently selected from CR 9 .
[0207] In certain embodiments, the present invention provides compounds of formula I, wherein R 9 Selected from H, halogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
[0208] In certain embodiments, the present invention provides compounds of formula I, wherein R 9 Selected from H, F, Cl, methyl and trifluoromethyl.
[0209] In certain embodiments, the present invention provides compounds of formula I, wherein X 1 For CH, CF, CCl, C(CH3), C(CF3) and N.
[0210] In certain embodiments, the present invention provides compounds of formula I, wherein X 1 For CH.
[0211] In certain embodiments, the present invention provides compounds of formula I, wherein X 2 Selected from CH and N.
[0212] In certain embodiments, the present invention provides compounds of formula I, wherein X 2 Selected from CH.
[0213] In certain embodiments, the present invention provides compounds of formula I, wherein X 3 Selected from N.
[0214] In certain embodiments, the present invention provides compounds of formula I wherein m is 0 or 1.
[0215] In certain embodiments, the present invention provides compounds of formula I wherein m is 0.
[0216] In certain embodiments, the present invention provides compounds of formula I, wherein n is 0, 1 or 2, for example, n is 1 or 2.
[0217] In certain embodiments, the present invention provides compounds of formula I wherein p is 1.
[0218] In certain embodiments, the present invention provides Formula I further represented by Formula I-1 or I-2,
[0219] Among them, ring A, R, R 2 、R 4 As defined above, q is 0, 1 or 2, for example 1 or 2.
[0220] In some embodiments, the present invention provides a compound of Formula IA or a pharmaceutically acceptable salt, stereoisomer, tautomer, or isotopically labeled compound thereof:
[0221] Among them, ring A, R 1 、R 2 、R 3 、R 4 、X 1 、X 2 , m, n are as defined above.
[0222] In some embodiments, Formula I is further Formula IA-1 or IA-2:
[0223] Among them, ring A, R 1 、R 2 、R 4 、X 1 、X 2 , m is as defined above, q is 0, 1 or 2, for example 1 or 2.
[0224] In some embodiments, Formula I is further Formula IA-1a, IA-1b, IA-2a, or IA-2b:
[0225] Among them, ring A, R 1 、R 2 、R 4 、X 1 、X 2 , m is as defined above, q is 0, 1 or 2, for example 1 or 2.
[0226] In some embodiments, the present invention provides a compound of Formula IB or a pharmaceutically acceptable salt, stereoisomer, tautomer, or isotopically labeled compound thereof:
[0227] Among them, ring A, R 1 、R 2 、R 3 、R 4 、X 1 、X 2 , m, n are as defined above.
[0228] In certain embodiments, the present invention provides a compound of Formula IA or IB, wherein:
[0229] Ring A is selected from phenyl and pyridyl;
[0230] R 1 Each independently selected from H and C 1-4 alkyl;
[0231] R 2 For LR 2 ';
[0232] L is selected from a direct bond or -(CR 5 R 6 ) p -;
[0233] R 5 and R 6 Each independently selected from H and C 1-4 alkyl;
[0234] R 2 'Independently selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, C 3-6 Cycloalkyl and 5-10 membered heteroaryl (e.g. 5-6 membered heteroaryl), wherein the alkyl, heteroalkyl, cycloalkyl, heteroaryl are optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocyclic substitution;
[0235] R 3 Selected from H and C 1-4 alkyl;
[0236] R 4 Each occurrence is independently selected from H, halogen, C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy, 5-10 membered heteroaryl, said heteroaryl being optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 haloalkyl substituted; or, R 3 and R 4 The atoms to which it is attached together form a 3-8 membered heterocyclic ring;
[0237] X 1 and X 2 Each independently selected from CR 9 and N, preferably, X 1 and X 2 Each independently selected from CR 9 ;
[0238] R 9 Selected from H, halogen, C 1-3 Alkyl and C 1-3 alkyl halide;
[0239] m is 0 or 1;
[0240] n is 1 or 2;
[0241] p is 1.
[0242] In certain embodiments, the present invention provides a compound of Formula IA or IB, wherein:
[0243] Ring A is selected from phenyl and pyridyl;
[0244] R 1 are each independently selected from H and methyl;
[0245] L is selected from a direct bond, -CH2- and -CH(CH3)-;
[0246] R 2 'Independently selected from methyl, pyrimidinyl, pyridinyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, Pyrazolyl and -CH2-O-CH3, wherein the methyl, pyrimidinyl, pyridyl, cyclopropyl, cyclobutyl, cyclopentyl and pyrazolyl are optionally substituted by methyl or F;
[0247] R 3 Selected from H and C 1-4 alkyl;
[0248] R 4 Each occurrence is independently selected from H, halogen, C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy, 5-6 membered heteroaryl, said heteroaryl being optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 haloalkyl substituted; or, R 3 and R 4 The atoms to which it is attached together form a 3-8 membered heterocyclic ring;
[0249] X 1 and X 2 Each independently selected from CR 9 and N;
[0250] R 9 Selected from H, F, Cl, C 1-3 Alkyl (such as methyl) and C 1-3 Haloalkyl (e.g., trifluoromethyl);
[0251] m is 0 or 1; n is 1 or 2.
[0252] In certain embodiments, the present invention provides a compound of Formula IA or IB, wherein:
[0253] Ring A is selected from phenyl and pyridyl;
[0254] R 1 Each independently selected from H and C 1-4 alkyl;
[0255] L is selected from a direct bond or -(CR 5 R 6 ) p -;
[0256] R 5 and R 6 Each independently selected from H and C 1-4 alkyl;
[0257] R 2 'Independently selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, C 3-6 Cycloalkyl and C 5-6 Heteroaryl, the alkyl, heteroalkyl, cycloalkyl, heteroaryl are optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 heterocyclic substitution;
[0258] R 3 Selected from H and C 1-4 alkyl;
[0259] R 4 Each occurrence is independently selected from H, halogen, C 1-4 Halogenated alkyl, C 1-4 Halogenated alkoxy, C 5-10 Heteroaryl, optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 haloalkyl substituted; or, R 3 and R 4 Together they form a 3-8 membered heterocyclic ring;
[0260] X 1 and X 2 Each independently selected from CR9 ;
[0261] R 9 Selected from H, halogen, C 1-3 Alkyl and C 1-3 alkyl halide;
[0262] m is 0 or 1;
[0263] n is 1 or 2;
[0264] p is 1.
[0265] In certain embodiments, the present invention provides a compound of Formula IA or IB, wherein:
[0266] Ring A is selected from phenyl and pyridyl;
[0267] R 1 are each independently selected from H and methyl;
[0268] L is selected from a direct bond, -CH2- and -CH(CH3)-;
[0269] R 2 'Independently selected from methyl, pyrimidinyl, pyridinyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, Pyrazolyl and -CH2-O-CH3, wherein the methyl, pyrimidinyl, pyridyl, cyclopropyl, cyclobutyl, cyclopentyl, pyrazolyl are optionally substituted with methyl, ethyl, propyl, F, Cl, Br and I;
[0270] R 3 Selected from H and C 1-4 alkyl;
[0271] R 4 Each occurrence is independently selected from C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy and Or, R 3 and R 4 The atoms to which it is attached together form a 5-6 membered heterocyclic ring;
[0272] X 1 and X 2 Each independently selected from CR 9 ;
[0273] R 9 Selected from H, F, Cl, C 1-3 Alkyl (such as methyl) and C 1-3 Haloalkyl (e.g., trifluoromethyl);
[0274] m is 0 or 1;
[0275] n is 1 or 2.
[0276] In certain embodiments, the present invention provides a compound of Formula IA or IB, wherein:
[0277] Ring A is selected from phenyl and pyridyl;
[0278] R 1 are each independently selected from H and methyl;
[0279] L is selected from a direct bond, -CH2- and -CH(CH3)-;
[0280] R 2 'Independently selected from methyl, pyrimidinyl, pyridinyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, Pyrazolyl and -CH2-O-CH3, wherein the methyl, pyrimidinyl, pyridyl, cyclopropyl, cyclobutyl, cyclopentyl and pyrazolyl are optionally substituted by methyl or F;
[0281] R 3 Selected from H and C 1-4 alkyl;
[0282] R 4 Each occurrence is independently selected from C 1-4 Haloalkyl and C 1-4 Haloalkoxy; or, R 3 and R 4 The atoms to which it is attached together form a 5-6 membered heterocyclic ring;
[0283] X 1 and X 2 Each independently selected from CR 9 ;
[0284] R 9 Selected from H, F, Cl, C 1-3 Alkyl (such as methyl) and C 1-3 Haloalkyl (e.g., trifluoromethyl);
[0285] m is 0 or 1;
[0286] n is 1 or 2.
[0287] In certain embodiments, the present invention provides a compound of Formula IA or IB, wherein:
[0288] Ring A is selected from phenyl and pyridyl;
[0289] R 1 are each independently selected from H and methyl;
[0290] L is selected from a direct bond, -CH2- and -CH(CH3)-;
[0291] R2 'Independently selected from methyl, pyrimidinyl, isopropyl, cyclopropyl, Pyrazolyl and -CH2-O-CH3, wherein the methyl, cyclopropyl and pyrazolyl are optionally substituted with methyl;
[0292] R 3 Selected from H and C 1-4 alkyl;
[0293] R 4 Each occurrence is independently selected from C 1-4 haloalkyl; or, R 3 and R 4 The atoms to which it is attached together form a 5-6 membered heterocyclic ring;
[0294] X 1 and X 2 Each independently selected from CR 9 ;
[0295] R 9 is H;
[0296] m is 0 or 1; n is 1 or 2.
[0297] In some embodiments, in the compounds of Formula I, I-1, I-2, IA, IB, IA-1, IA-2, IA-1a, IA-1b, IA-2a, or IA-2b of the present invention, one or more of the following are satisfied:
[0298] (1) Ring A is selected from phenyl and pyridyl; preferably selected from phenyl;
[0299] (2)R 1 Each independently is H;
[0300] (3)X 1 and X 2 Each independently selected from CR 9 and N; preferably selected from CR 9 ;
[0301] (4)R 2 'Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 2-6 Heteroalkyl, non-cyclopropyl C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl and non-pyrazolyl 5-10 membered heteroaryl, preferably selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C2-6 Heteroalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl, or preferably selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, non-cyclopropyl C 3-6 Cycloalkyl and non-pyrazolyl 5-10 membered heteroaryl, preferably selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, cyclobutyl, cyclopentyl, Pyrimidinyl, pyridinyl, preferably selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, said alkyl, alkoxy, hydroxyalkyl, heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted with one or more halogen, -OH, -CN, -NR 7 R 8 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic group, C 6-10 aryl substitution;
[0302] (5)R 4 is independently selected at each occurrence from H, -OH, halogen, -CN, -NR 7 R 8 、-NHCOCH3、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl and non-pyrazolyl 5-10 membered heteroaryl, preferably selected from H, -OH, halogen, -CN, -NR 7 R 8 、-NHCOCH3、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl, preferably selected from H, halogen, CN, -NR 7 R 8 、C 1-4Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, preferably selected from H, halogen, C 1-4 Halogenated alkyl, C 1-4 Halogenated alkoxy, non-pyrazolyl 5-10 membered heteroaryl, preferably selected from C 1-4 Haloalkyl and C 1-4 Halogenated alkoxy, preferably selected from C 1-4 Haloalkyl, the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted by one or more halogen, -CN, -NR 5 R 6 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic substitution;
[0303] (6)R 5 and R 6 Each independently selected from H, C 1-4 alkyl;
[0304] (7)R 9 are each independently selected from halogen, C 1-4 Alkyl and C 1-4 Haloalkyl, preferably selected from halogen, preferably selected from F;
[0305] (8) m is 0 or 1, preferably 0;
[0306] (9) n is 0, 1 or 2, preferably 1 or 2;
[0307] (10) p is 1;
[0308] (11) q is 0, 1 or 2, preferably 1 or 2.
[0309] In some embodiments, the present invention provides compounds of Formula IA-1, wherein,
[0310] Ring A is selected from phenyl and pyridyl;
[0311] R 1 Each independently is H;
[0312] X 1 and X 2 Each independently selected from CR 9and N, preferably selected from CR 9 ;
[0313] R 2 For LR 2 ';
[0314] L is selected from a direct bond or -(CR 5 R 6 ) p -;
[0315] R 2 'Independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 2-6 Heteroalkyl, non-cyclopropyl C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl and non-pyrazolyl 5-10 membered heteroaryl, the alkyl, alkoxy, hydroxyalkyl, heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted with one or more halogen, -OH, -CN, -NR 7 R 8 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic group, C 6-10 aryl substitution;
[0316] R 4 is independently selected at each occurrence from H, -OH, halogen, -CN, -NR 7 R 8 、-NHCOCH3、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl and non-pyrazolyl 5-10 membered heteroaryl, the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted with one or more halogen, -CN, -NR 5 R 6 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6Cycloalkyl, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic substitution;
[0317] R 5 and R 6 Each independently selected from H and C 1-4 alkyl;
[0318] R 7 and R 8 Each independently selected from H and C 1-4 alkyl;
[0319] R 9 are each independently selected from halogen, C 1-4 Alkyl and C 1-4 alkyl halide;
[0320] m is 0 or 1;
[0321] q is 1 or 2;
[0322] And p is 1.
[0323] In some embodiments, the present invention provides compounds of Formula IA-1, wherein,
[0324] Ring A is selected from phenyl and pyridyl;
[0325] R 1 Each independently is H;
[0326] X 1 and X 2 Each independently selected from CR 9 and N, preferably selected from CR 9 ;
[0327] R 2 For LR 2 ';
[0328] L is selected from a direct bond or -(CR 5 R 6 ) p -;
[0329] R 2 'Independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 2-6 Heteroalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl, the alkyl, alkoxy, hydroxyalkyl, heteroalkyl, heterocyclyl, cycloalkoxy, aryl are optionally substituted by one or more halogen, -OH, -CN, -NR 7 R 8 、C1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic group, C 6-10 aryl substitution;
[0330] R 4 is independently selected at each occurrence from H, -OH, halogen, -CN, -NR 7 R 8 、-NHCOCH3、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl, the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl are optionally substituted by one or more halogen, -CN, -NR 5 R 6 、C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic substitution;
[0331] R 5 and R 6 Each independently selected from H and C 1-4 alkyl;
[0332] R 7 and R 8 Each independently selected from H and C 1-4 alkyl;
[0333] R 9 are each independently selected from halogen, C 1-4 Alkyl and C 1-4 alkyl halide;
[0334] m is 0 or 1;
[0335] q is 1 or 2;
[0336] And p is 1.
[0337] In some embodiments, the present invention provides a compound of Formula I, I-1, I-2, IA, IB, IA-1, IA-2, IA-1a, IA-1b, IA-2a, or IA-2b that satisfies one or more of the following:
[0338] (1)X 1 and X 2 Each independently selected from CR 9 ;
[0339] (2)R 2 'Independently selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, said alkyl, heteroalkyl is optionally replaced by C 1-4 Alkyl or halogen substituted;
[0340] (3)R 4 Each occurrence is independently selected from C 1-4 Haloalkyl and C 1-4 haloalkoxy;
[0341] (4)R 9 are each independently selected from halogen.
[0342] The present invention covers any combination of the above embodiments.
[0343] In some embodiments, compounds of the present invention include, but are not limited to:
[0344] In some embodiments, the compound of the present invention is not:
[0345] Preparation method
[0346] In certain embodiments, the present invention provides a method for preparing a compound of Formula IA comprising the steps of:
[0347] Route A
[0348] Step 1: Compound IA-1 and IA-2 undergo condensation reaction to produce compound IA-3;
[0349] Step 2: Compound IA-3 is heated under acidic conditions for deprotection to generate compound IA;
[0350] in:
[0351] Each group is as defined above;
[0352] The reaction conditions of each step are as follows:
[0353] Step 1: Compounds IA-1 and IA-2 undergo condensation reaction (e.g., HATU and DIPEA; POCl3 and pyridine, etc.) to generate compound IA-3;
[0354] Step 2: Compound IA-3 is heated and deprotected under acidic conditions (trifluoroacetic acid, etc. is used as the acid) to generate compound IA;
[0355] The synthesis method of the compound of formula IB is similar to the above method.
[0356] Pharmaceutical compositions, preparations and methods of treatment
[0357] In some embodiments, the present invention provides a pharmaceutical composition comprising a prophylactically or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotopically labeled compound thereof and one or more pharmaceutically acceptable carriers.
[0358] In some embodiments, the present invention provides a pharmaceutical formulation selected from the group consisting of a solid formulation, a semisolid formulation, a liquid formulation, and a gaseous formulation.
[0359] In some embodiments, the pharmaceutical composition or pharmaceutical formulation may further comprise one or more additional therapeutic agents.
[0360] In some embodiments, the pharmaceutical composition or pharmaceutical formulation is administered orally, intravenously, intraarterially, subcutaneously, intraperitoneally, intramuscularly, or transdermally.
[0361] In some embodiments, the present invention provides the use of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, or a pharmaceutical composition of the present invention, or a pharmaceutical formulation of the present invention in the preparation of a medicament for preventing or treating a disease or condition associated with PRMT5 activity.
[0362] In some embodiments, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, or a pharmaceutical composition of the present invention, or a pharmaceutical formulation of the present invention for the preparation of a medicament for modulating (e.g., reducing or inhibiting) PRMT5 activity.
[0363] In some embodiments, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, or a pharmaceutical composition of the present invention, or a pharmaceutical formulation of the present invention, for use in preventing or treating a disease or condition associated with PRMT5 activity.
[0364] In some embodiments, the present invention provides a method for preventing or treating a disease or condition associated with PRMT5 activity, comprising administering to an individual in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, or a pharmaceutical composition of the present invention, or a pharmaceutical formulation of the present invention.
[0365] In some embodiments, the disease or condition associated with PRMT5 activity is a cancer or tumor in which MTAP is deficient.
[0366] In some embodiments, the cancer or tumor is selected from esophageal cancer, lung cancer, pancreatic cancer, glioblastoma, bile duct cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular carcinoma, prostate cancer, melanoma, gastric cancer, colon cancer, leukemia (B-CLL) and lymphoma.
[0367] In the present invention, "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle that is administered together with the therapeutic agent and is suitable for contact with the tissues of humans and / or other animals without excessive toxicity, irritation, allergic response or other problems or complications corresponding to a reasonable benefit / risk ratio within the scope of reasonable medical judgment.
[0368] Pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, sterile liquids. Examples of suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1990).
[0369] The pharmaceutical compositions of the present invention can act systemically and / or locally. For this purpose, they can be administered by any suitable route.
[0370] For these administration routes, the pharmaceutical composition of the present invention can be administered in suitable dosage forms.
[0371] As used herein, the term "effective amount" refers to that amount of a compound which, when administered, relieves to some extent one or more of the symptoms of the condition being treated.
[0372] The dosage regimen can be adjusted to provide the optimal desired response. For example, a single bolus can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. It is to be noted that dosage values can vary with the type and severity of the condition to be alleviated and can include single or multiple doses. It is to be further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering or supervising the administration of the composition.
[0373] The amount of the compound of the present invention administered will depend on the severity of the individual, disease or the patient's condition, the speed of administration, the disposal of the compound and the judgment of the prescribing physician for treatment. Generally speaking, effective dose is about 0.0001 to about 50 mg per kg body weight per day. In some cases, the dosage level not higher than the lower limit of the aforementioned range can be enough, and in other cases, still can adopt larger doses when not causing any harmful side effects, condition is first divided into several smaller doses to be administered throughout the day.
[0374] The compound of the present invention may be contained in a pharmaceutical composition or formulation in an amount ranging from about 0.01 mg to about 1000 mg.
[0375] Unless otherwise indicated, as used herein, the term "prevention" refers to the preemptive administration of a drug to avoid or prevent the appearance of one or more symptoms of a disease or condition. One of ordinary skill in the medical arts recognizes that the term "prevention" is not an absolute term. In the medical arts, it is understood that a drug is administered prophylactically to substantially reduce the likelihood or severity of a condition or the symptoms of a condition, which is the meaning intended in this disclosure. The Physician's Desk Reference, a standard text in the field, uses the term "prevention" hundreds of times. As used therein, the term "prevention" with respect to a condition or disease refers to avoiding the cause, effect, symptom, or progression of the disease or condition before the disease or condition fully manifests itself.
[0376] The term "treating" means to reverse, alleviate, inhibit the progress of the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
[0377] As used herein, "subject" includes humans and non-human animals. Exemplary human subjects include human subjects suffering from diseases (e.g., the diseases described herein) (referred to as patients) or normal individuals. "Non-human animals" herein include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0378] In some embodiments, the pharmaceutical compositions or pharmaceutical formulations of the present invention may further comprise one or more additional therapeutic or prophylactic agents (e.g., other drugs used to treat cancer or tumor diseases). In some embodiments, the therapeutic methods of the present invention may further comprise administering one or more additional therapeutic or prophylactic agents (e.g., other drugs used to treat cancer or tumor diseases). DETAILED DESCRIPTION
[0379] Example
[0380] The present invention is further described below in conjunction with examples, but these examples are not intended to limit the scope of the present invention. The abbreviations used herein have the following meanings:
[0381] The compounds of the present invention are separated and purified by preparative TLC, silica gel column chromatography, Prep-HPLC and / or flash column chromatography (Flash column chromatography). 1 The reaction was confirmed by H NMR and / or MS. Reaction monitoring was performed by TLC or LC-MS.
[0382] 1 H NMR spectroscopy was performed using a Bruker superconducting nuclear magnetic resonance spectrometer (model AVACE III HD 400 MHz).
[0383] LC / MS uses Aglient 1260 Infinity / Aglient 6120 Quadrupole.
[0384] TLC used silica gel GF 254 as the stationary phase.
[0385] Column chromatography generally uses 200-300 mesh silica gel (Qingdao Ocean) as the stationary phase.
[0386] Flash column chromatography was performed using a Biotage flash column chromatograph.
[0387] Prep-HPLC used Agilent 1260 and Waters 2489.
[0388] Microwave reactions were performed using a BiotageInitiator microwave reactor.
[0389] In the following examples, unless otherwise specified, the reaction temperature is room temperature (15-30°C).
[0390] The reagents used in this application were purchased from Acros Organics, Aldrich Chemical Company, or Teber Chemical Company.
[0391] Synthesis Example:
[0392] Intermediate Int-A: 4-((2,4-dimethylbenzyl)amino)imidazo[1,5-a]quinoxaline-8-carboxylic acid
[0393] Step 1: Synthesis of intermediate N-(4-bromo-2-fluorophenyl)-1H-imidazole-5-carboxamide (Compound Int A-3)
[0394] Int A-1 (15 g, 133.83 mmol) was dissolved in anhydrous DMF (50 mL) under an ice-water bath. DIPEA (34.59 g, 267.65 mmol) was slowly added dropwise. After stirring, a solution of HATU (76.33 g, 200.74 mmol) in anhydrous DMF was added dropwise. Stirring was continued for 1 hour. Finally, a solution of Int A-2 (27.97 g, 147.21 mmol) in anhydrous DMF was added dropwise. The temperature was naturally raised to 25°C and the reaction was allowed to proceed for 16 hours. After the reaction, water was added and stirred. The mixture was extracted with ethyl acetate and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase PE:EA = 40:60) to obtain the intermediate Int A-3 (16.00 g). MS (ESI, m / z): 284.0 [M+H]. + .
[0395] Step 2: Synthesis of intermediate 8-bromoimidazo[1,5-a]quinoxaline-4(5H)-one (Compound Int A-4)
[0396] Int A-3 (2.27 g, 7.98 mmol) was dissolved in anhydrous DMAc (20 mL). NaH (479.01 mg, 11.98 mmol) was added portionwise under ice-cooling. The mixture was stirred for 10 minutes and then reacted at 140°C under nitrogen atmosphere for 48 hours. After completion of the reaction, the DMAc was mostly evaporated under reduced pressure. The mixture was cooled to room temperature, stirred with water, and filtered. The filter cake was rinsed twice with water to obtain the intermediate Int A-4 (2.0 g), which was dried and used. MS (ESI, m / z): 264.0 [M+H] + .
[0397] Step 3: Synthesis of intermediate 4-oxo-4,5-dihydroimidazo[1,5-a]quinoxaline-8-carboxylic acid methyl ester (Compound Int A-5)
[0398] Int A-4 (2.0 g, 7.57 mmol), TEA (2.30 g, 22.72 mmol), and Pd(dppf)2Cl2 (613.90 mg, 757.35 μmol) were added to an autoclave and dissolved in methanol (30 mL). After CO displacement, the pressure was increased to 1.2 atm and the reaction was continued at 120°C for 16 hours. After completion of the reaction, the temperature was cooled to room temperature and filtered. The filter cake, intermediate Int A-5 (700 mg), was dried and used. MS (ESI, m / z): 244.1 [M+H]+.
[0399] Step 4: Synthesis of intermediate 4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]quinoxaline-8-carboxylic acid methyl ester (Compound Int A-7)
[0400] In anhydrous DMF (20 mL) was added with Int A-5 (700 mg, 2.88 mmol) and PyBOP (2.25 g, 4.32 mmol) under ice. DIPEA (1.12 g, 8.63 mmol) was then added dropwise and stirred for 10 min. Finally, Int A-6 (962.46 mg, 5.76 mmol) was added and the mixture was allowed to react at 60°C for 16 hr. After completion of the reaction, water was added and stirred. The mixture was extracted with EA and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 95:5) to obtain intermediate Int A-7 (904 mg). MS (ESI, m / z): 393.2 [M+H] + .
[0401] Step 5: Synthesis of the intermediate 4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]quinoxaline-8-carboxylic acid (Compound Int A)
[0402] Int A-7 (904 mg, 2.30 mmol) was dissolved in 30 mL of methanol under ice-cooling. A 15 mL aqueous solution of NaOH (552.90 mg, 13.82 mmol) was added dropwise. The temperature was naturally raised to 25°C and the reaction was allowed to proceed for 16 hours. After the reaction, the methanol was evaporated and dilute hydrochloric acid was added dropwise to the remaining portion under ice-cooling until the solution became acidic. The solution was filtered and the filter cake was washed twice with water to obtain the intermediate Int A (840 mg). MS (ESI, m / z): 379.2 [M+H] + .
[0403] Intermediate Int-B: 5-(bis(4-methoxybenzyl)amino)imidazo[1,5-c]quinazoline-9-carboxylic acid
[0404] Step 1: Synthesis of 6-bromo-4-methylquinazolin-2-amine (Compound Int B-2)
[0405] Int B-1 (1 g, 4.67 mmol) and a 4M HCl solution in 1,4-dioxane (10 mL) were added to a reaction flask and stirred at room temperature for 20 min. The reaction solution was concentrated to dryness under reduced pressure, and then an aqueous cyanamide solution (5.00 mL) was added to the reaction flask. Under nitrogen protection, the reaction was continued at 50°C for 16 hours. After the reaction was completed, the reaction solution was cooled to room temperature and diluted with water. Saturated Na2CO3 solution was added to adjust the pH to 8-9. The mixture was filtered, the filter cake was washed with water, and dried to obtain compound Int B-2. MS (ESI, m / z): 238.0 [M+H] + .
[0406] Step 2: Synthesis of 9-bromoimidazo[1,5-c]quinazolin-5-amine (Compound Int B-3)
[0407] To a reaction flask, Int B-2 (1.1 g, 4.62 mmol), glycine (694 mg, 9.24 mmol), TBAI (341 mg, 924.05 μmol), DMSO (10 mL), AcOH (832 mg, 13.86 mmol), and TBHP (6 M, 3.08 mL) were added. The mixture was reacted at 95°C under nitrogen atmosphere for 16 hours. After completion of the reaction, the reaction solution was cooled to room temperature, diluted with water, and the pH was adjusted to 8-9 by adding saturated Na2CO3 solution. The mixture was filtered, the filter cake was washed with water, and dried to obtain compound Int B-3 (1 g). MS (ESI, m / z): 263.0 [M+H] + .
[0408] Step 3: Synthesis of 9-bromo-N,N-bis(4-methoxybenzyl)imidazo[1,5-c]quinazolin-5-amine (Compound Int B-4)
[0409] Int B-3 (200 mg, 760.19 μmol) and DMF (10 mL) were added to the reaction flask, dissolved, and cooled in an ice-water bath. NaH (122 mg, 3.04 mmol) was then added and the reaction continued in the ice-water bath for 30 minutes. p-PMBCl (357 mg, 2.28 mmol) was added and the reaction was continued at 0°C for 20 minutes before slowly warming to room temperature for 16 hours. The reaction solution was then diluted with water and extracted with ethyl acetate (30 ml x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase EA:PE = 35:65) and the resulting product was dried to give compound Int B-4 (130 mg). MS (ESI, m / z): 503.1 [M+H] + .
[0410] Step 4: Synthesis of methyl 5-(bis(4-methoxybenzyl)amino)imidazo[1,5-c]quinazoline-9-carboxylate (Compound Int B-5)
[0411] Int B-4 (130 mg, 258.25 μmol), Pd(dppf)Cl2·DCM (19 mg, 25.82 μmol), MeOH (10 mL), and TEA (78 mg, 774.75 μmol) were added to an autoclave. After displacing CO2 twice, the pressure was increased to 10-12 atmospheres and the temperature was raised to 120°C for 5 hours. After completion of the reaction, the mixture was diluted with water and extracted with ethyl acetate (30 ml x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase EA:PE = 35:65) to obtain compound Int B-5 (90 mg). MS (ESI, m / z): 483.2 [M+H] + .
[0412] Step 5: Synthesis of 5-(bis(4-methoxybenzyl)amino)imidazo[1,5-c]quinazoline-9-carboxylic acid (Compound Int B)
[0413] 212e (90 mg, 186.52 μmol) and THF (3 mL) were added to the reaction flask and dissolved. A solution of LiOH·H2O (20 mg, 466.29 μmol) in H2O (0.5 mL) was then added. The mixture was incubated at 50°C under nitrogen for 8 hours. After completion, the pH of the reaction solution was adjusted to 6-7 with 2M hydrochloric acid, and the solvent was concentrated to dryness under reduced pressure to yield compound Int B. MS (ESI, m / z): 469.2 [M+H] + .
[0414] Intermediate Int C: (R)-1-(pyrimidin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)ethan-1-amine (Int C)
[0415] Step 1: Synthesis of (R)-2-methyl-N-(1-(pyrimidin-2-yl)ethylidene)propane-2-sulfenamide (Compound Int C-3)
[0416] Int C-1 (1 g, 8.19 mmol) and Int C-2 (1.78 g, 9.83 mmol) were dissolved in anhydrous THF (20 mL). Ti(iPrO)4 (4.65 g, 16.38 mmol, 4.85 mL) was slowly added. After addition, the temperature was raised to 75°C and the reaction was allowed to proceed for 12 hours. After completion of the reaction, the temperature was lowered to room temperature to obtain compound Int C-3 (1.8 g), which was used directly in the next step. MS (ESI, m / z): 226.1 [M+H] + .
[0417] Step 2: Synthesis of (R)-2-methyl-N-((R)-1-(pyrimidin-2-yl)ethyl)propane-2-sulfenamide (Compound Int C-4)
[0418] NaBH4 (604.49 mg, 15.98 mmol) was added to the reaction flask containing Int C-3 (1.8 g, 7.99 mmol) from the previous step at 25°C. The reaction system was allowed to react for 2 hours at 25°C. After completion, an appropriate amount of water was added to quench the reaction, and the mixture was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 93:7) to obtain compound Int C-4 (1.5 g). MS (ESI, m / z): 228.1 [M+H] + .
[0419] Step 3: Synthesis of (R)-1-(pyrimidin-2-yl)ethane-1-amine (Compound Int C-5)
[0420] Int C-4 (1.5 g, 6.60 mmol) was dissolved in MeOH (15 mL), and then a 4N HCl solution in 1,4-dioxane (5 mL) was slowly added. The reaction system was allowed to react at 25°C for 1 hour. After completion of the reaction, the mixture was concentrated under reduced pressure and then dissolved in methanol. A few drops of triethylamine were added to adjust the pH to 7-8. The mixture was then concentrated under reduced pressure to obtain compound Int C-5 (800 mg). MS (ESI, m / z): 124.1 [M+H] + .
[0421] Step 4: Synthesis of (R)-1-(pyrimidin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)ethane-1-amine (Int C)
[0422] Int C-5 (600 mg, 1.46 mmol) and Int C-6 (255.93 mg, 1.46 mmol) were dissolved in anhydrous DCM (20 mL), and AcOH (175.53 mg, 2.92 mmol) was added. The resulting mixture was stirred at 25°C for 30 min. NaBH(OAc)3 (464.65 mg, 2.19 mmol) was then added. After the addition was complete, the reaction system was allowed to react at 25°C for 1.5 hr. After completion, the reaction was quenched with methanol and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (mobile phase DCM:MeOH = 92:8) to obtain compound Int C (230 mg). MS (ESI, m / z): 283.1 [M+H] + .
[0423] Intermediate Int D: 4-((2,4-dimethylbenzyl)amino)-3-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid (Int D)
[0424] Step 1: Synthesis of N-(4-bromo-2-fluorophenyl)-4-methyl-1H-imidazole-5-carboxamide (Compound Int D-2)
[0425] Int D-1 (5 g, 39.65 mmol) was dissolved in anhydrous DMF (60 mL) under an ice-water bath. DIPEA (10.25 g, 79.29 mmol) was slowly added dropwise. After stirring, a solution of HATU (22.61 g, 59.47 mmol) in anhydrous DMF was added dropwise. Stirring was continued for 1 hour. Finally, a solution of Int A-2 (8.29 g, 43.61 mmol) in anhydrous DMF was added dropwise. The temperature was naturally raised to 25°C and the reaction was allowed to proceed for 16 hours. After the reaction, water was added and the mixture was stirred. The mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase PE:EA = 40:60) to obtain compound Int D-2 (5.40 g). MS (ESI, m / z): 298.0 [M+H] + .
[0426] Step 2: Synthesis of 8-bromo-3-methylimidazo[1,5-a]quinoxaline-4(5H)-one (Compound Int D-3)
[0427] Int D-2 (5.40 g, 18.11 mmol) was dissolved in anhydrous DMAc (50 mL). 60% pure sodium hydride (1.09 g, 27.17 mmol) was added portionwise under ice-cooling. The mixture was stirred for 10 minutes and then reacted at 140°C for 48 hours. After completion of the reaction, the mixture was cooled to room temperature, stirred with water, and extracted with ethyl acetate, concentrated to afford compound Int D-3 (3.50 g). MS (ESI, m / z): 278.0 [M+H] + .
[0428] Step 3: Synthesis of 8-bromo-N-(2,4-dimethoxybenzyl)-3-methylimidazo[1,5-a]quinoxaline-4-amine (Compound Int D-4)
[0429] In anhydrous DMF (20 mL) was added with Int D-3 (2.00 g, 7.19 mmol) and PyBOP (7.48 g, 14.38 mmol) under ice. DIPEA (2.79 g, 21.57 mmol) was then added dropwise and stirred for 10 min. Finally, Int A-6 (2.40 g, 14.38 mmol) was added and the mixture was allowed to react at 60°C for 16 hr. After completion of the reaction, water was added and stirred, followed by extraction with ethyl acetate and concentration to obtain the crude product. The crude product was purified by reverse-phase HPLC (mobile phase: H2O [0.05% NH4HCO3]:ACN = 20:80) to afford compound Int D-4 (1.20 g). MS (ESI, m / z): 427.1 [M+H] + .
[0430] Step 4: Synthesis of methyl 4-((2,4-dimethoxybenzyl)amino)-3-methylimidazo[1,5-a]quinoxaline-8-carboxylate (Compound Int D-5)
[0431] Int D-4 (1.20 g, 2.81 mmol), TEA (852.54 mg, 8.43 mmol), and Pd(dppf)2Cl2 (227.64 mg, 280.84 μmol) were added to an autoclave and dissolved in methanol (30 mL). After carbon monoxide substitution, the pressure was increased to 1.2 atm and the reaction was continued at 120°C for 16 hours. After completion of the reaction, the temperature was cooled to room temperature and filtered, yielding the filter cake containing compound Int D-5 (614 mg). MS (ESI, m / z): 407.2 [M+H] + .
[0432] Step 5: Synthesis of 4-((2,4-dimethoxybenzyl)amino)-3-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid (Compound Int D)
[0433] Int D-5 (614 mg, 1.51 mmol) was dissolved in methanol (10 mL) under ice-cooling. A 2 mL aqueous solution of sodium hydroxide (181.28 mg, 4.53 mmol) was added dropwise. The mixture was allowed to react at 55°C for 3 hours. After the reaction, the methanol was evaporated and dilute hydrochloric acid was added dropwise to the remaining portion under ice-cooling until the solution became acidic. The mixture was filtered and the filter cake was washed twice with water to obtain compound Int D (446 mg). MS (ESI, m / z): 393.1 [M+H] + .
[0434] Intermediate Int E: (S)-N-methyl-6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-amine (Int E)
[0435] Step 1: Synthesis of tert-butyl (S)-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)carbamate (Int E-2)
[0436] Int E-1 (200 mg, 984.44 μmol) and TEA (109.58 mg, 1.08 mmol) were dissolved in DCM (15 mL) under an ice-water bath. (Boc)2O (214.85 mg, 984.44 μmol) was slowly added, and the mixture was allowed to warm to 25°C and react for 16 hours. After completion of the reaction, the mixture was concentrated and washed with silica gel. The sample was then purified by silica gel column chromatography (mobile phase: DCM:MeOH = 98:2) to obtain compound Int E-2 (295.45 mg).
[0437] Step 2: Synthesis of tert-butyl (S)-methyl (6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)carbamate (Int E-3)
[0438] Int E-2 (100 mg, 329.73 μmol) was dissolved in anhydrous THF (10 mL). 60% pure sodium hydride (19.78 mg, 494.60 μmol) was added portionwise under ice-cooling. After stirring for 15 minutes, iodomethane (51.48 mg, 362.71 μmol) was added dropwise. The mixture was reacted at 0°C for 16 hours. After completion of the reaction, the sample was directly concentrated and washed with silica gel. It was then purified by silica gel column chromatography (mobile phase DCM:MeOH = 100:0) to obtain compound Int E-3 (100.00 mg).
[0439] Step 3: Synthesis of (S)-N-methyl-6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-amine (Int E) hydrochloride
[0440] Int E-3 (100 mg, 315.16 μmol) was dissolved in dichloromethane (9 mL). 4 M dioxane hydrochloride solution (1.5 mL) was added dropwise at 0°C. The temperature was naturally raised to 25°C and the reaction was allowed to proceed for 6 hours. After completion of the reaction, the mixture was concentrated to obtain Int E hydrochloride (68.8 mg). MS (ESI, m / z): 218.2 [M+H] + .
[0441] Intermediate Int F: 4-((2,4-dimethoxybenzyl)amino)-7-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid (Int F)
[0442] Step 1: Synthesis of N-(4-bromo-2-fluoro-5-methylphenyl)-1H-imidazole-5-carboxamide (Int F-2)
[0443] Int A-1 (3 g, 26.77 mmol) was dissolved in anhydrous DMF (50 mL) under an ice-water bath. DIPEA (6.92 g, 53.53 mmol) was slowly added dropwise. After stirring, a solution of HATU (15.27 g, 40.15 mmol) in anhydrous DMF was added dropwise. Stirring was continued for 1 hour. Finally, a solution of Int F-1 (6.01 g, 29.44 mmol) in anhydrous DMF was added dropwise. The temperature was naturally raised to 25°C and the reaction was allowed to proceed for 16 hours. After the reaction, water was added and the mixture was stirred. The mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase PE:EA = 15:85) to obtain compound Int F-2 (5.65 g). MS (ESI, m / z): 298.0 [M+H] + .
[0444] Step 2: Synthesis of 8-bromo-7-methylimidazo[1,5-a]quinoxalin-4(5H)-one (Int F-3)
[0445] Int F-2 (5.65 g, 18.95 mmol) was dissolved in anhydrous DMAc (35 mL). NaH (1.14 g, 28.43 mmol) was added portionwise under ice-cooling. The mixture was stirred for 10 minutes and then reacted at 140°C for 48 hours. After completion of the reaction, the mixture was cooled to room temperature and naturally precipitated. Compound Int F-3 (1.70 g) was obtained by filtration and dried. The crude product was used as is. MS (ESI, m / z): 278.0 [M+H] + .
[0446] Step 3: Synthesis of 8-bromo-N-(2,4-dimethoxybenzyl)-7-methylimidazo[1,5-a]quinoxaline-4-amine (Int F-4)
[0447] In anhydrous DMF (20 mL) was added with Int F-3 (700 mg, 2.52 mmol) and PyBOP (1.96 g, 3.78 mmol) under ice. DIPEA (975.91 mg, 7.55 mmol) was then added dropwise and stirred for 10 min. Finally, Int A-6 (841.72 mg, 5.03 mmol) was added and the mixture was allowed to react at 60°C for 16 hr. After completion of the reaction, water was added and stirred. The mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by reverse-phase HPLC column chromatography (mobile phase: H2O:ACN = 20:80) to obtain compound Int F-4 (900 mg). MS (ESI, m / z): 427.0 [M+H] + .
[0448] Step 4: Synthesis of methyl 4-((2,4-dimethoxybenzyl)amino)-7-methylimidazo[1,5-a]quinoxaline-8-carboxylate (Int F-5)
[0449] Int F-4 (800 mg, 1.87 mmol), TEA (568.36 mg, 5.62 mmol), and Pd(dppf)2Cl2 (151.76 mg, 187.22 μmol) were added to an autoclave and dissolved in 30 mL of methanol. After carbon monoxide substitution, the pressure was increased to 1.2 atm and the reaction was continued at 120°C for 16 hours. After completion of the reaction, the temperature was cooled to room temperature and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 96:4) to obtain compound Int F-5 (332 mg), which was dried and used. MS (ESI, m / z): 407.1 [M+H] + .
[0450] Step 5: Synthesis of 4-((2,4-dimethoxybenzyl)amino)-7-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid (Int F)
[0451] Int F-5 (332 mg, 816.86 μmol) was dissolved in methanol (10 mL) under ice-cooling. A 2 mL aqueous solution of NaOH (98.02 mg, 2.45 mmol) was added dropwise. The mixture was allowed to react at 55°C for 3 hours. After the reaction, the methanol was evaporated and dilute hydrochloric acid was added dropwise to the remaining portion under ice-cooling until the solution became acidic. The mixture was filtered and the filter cake was washed twice with water to obtain compound Int F (236.80 mg). The product was dried and used without further purification. MS (ESI, m / z): 393.1 [M+H] + .
[0452] Intermediate Int G: 4-((2,4-dimethoxybenzyl)amino)-7-trifluoromethylimidazo[1,5-a]quinoxaline-8-carboxylic acid (Int G)
[0453] Step 1: Synthesis of N-(4-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-1H-imidazole-5-carboxamide (Int G-2)
[0454] Int A-1 (2.17 g, 19.38 mmol) was dissolved in anhydrous DMF (50 mL) under an ice-water bath. DIPEA (3.76 g, 29.07 mmol) was slowly added dropwise. After stirring, HATU (8.84 g, 23.25 mmol) was added and stirring continued for 1 hour. Finally, Int G-1 (5 g, 19.38 mmol) was added and the temperature was naturally raised to 25°C for 16 hours. After the reaction, water was added with stirring, and the mixture was extracted with EA and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase PE:EA = 47:53) to obtain compound Int G-2 (1.55 g). MS (ESI, m / z): 351.9 [M+H] + .
[0455] Step 2: Synthesis of 8-bromo-7-(trifluoromethyl)imidazo[1,5-a]quinoxalin-4(5H)-one (Int G-3)
[0456] Int G-2 (1.55 g, 4.40 mmol) was dissolved in anhydrous DMAc (50 mL). Sodium hydride (264.14 mg, 6.60 mmol) was added portionwise under ice-cooling. The mixture was stirred for 10 minutes and then reacted at 100°C for 12 hours. After completion of the reaction, the mixture was cooled to room temperature, stirred with water, and extracted with ethyl acetate, concentrated to yield compound Int G-3 (1.40 g). MS (ESI, m / z): 332.0 [M+H] + .
[0457] Step 3: Synthesis of 8-bromo-N-(2,4-dimethoxybenzyl)-7-(trifluoromethyl)imidazo[1,5-a]quinoxaline-4-amine (Int G-4)
[0458] In anhydrous DMF (5 mL) was added with Int G-3 (0.40 g, 1.20 mmol) and PyBOP (940.25 mg, 1.81 mmol) under an ice bath. DIPEA (467.03 mg, 3.61 mmol) was then added dropwise and stirred for 10 min. Finally, Int A-6 (302.11 mg, 302.11 mg) was added and the mixture was allowed to react at 60°C for 16 hr. After completion of the reaction, water was added and stirred, followed by extraction with ethyl acetate and concentration to obtain a crude product. The crude product was purified by reverse-phase HPLC column chromatography (mobile phase: H2O:ACN = 36:64) to obtain compound Int G-4 (0.25 g). MS (ESI, m / z): 481.1 [M+H] + .
[0459] Step 4: Synthesis of methyl 4-((2,4-dimethoxybenzyl)amino)-7-(trifluoromethyl)imidazo[1,5-a]quinoxaline-8-carboxylate (Int G-5)
[0460] Int G-4 (0.25 g, 519.46 μmol), TEA (157.69 mg, 1.56 mmol), and Pd(dppf)2Cl2 (42.11 mg, 51.95 μmol) were added to an autoclave and dissolved in methanol (10 mL). After carbon monoxide substitution, the pressure was increased to 1.2 atm and the reaction was continued at 120°C for 12 hours. After completion of the reaction, the reaction was cooled to room temperature, filtered, and concentrated under reduced pressure. Prep-TLC (PE:EA = 8:2) was used to separate and purify the product to obtain compound Int G-5 (70 mg). MS (ESI, m / z): 461.1 [M+H] + .
[0461] Step 5: Synthesis of 4-((2,4-dimethoxybenzyl)amino)-7-(trifluoromethyl)imidazo[1,5-a]quinoxaline-8-carboxylic acid (Int G)
[0462] Int G-5 (70 mg, 152.04 μmol) was dissolved in ethanol (10 mL) and H₂O (2 mL). NaOH (12.16 mg, 304.08 μmol) was added and the mixture was reacted at 55°C for 3 hours. After completion of the reaction, the solvent was removed by concentration under reduced pressure to obtain compound Int G (65 mg). MS (ESI, m / z): 447.1 [M+H] + .
[0463] Intermediate Int H: N-methyl-6-(trifluoromethyl)isochroman-4-amine (Int H)
[0464] Step 1: Synthesis of 1-((allyloxy)methyl)-2-bromo-4-(trifluoromethyl)benzene (Compound Int H-2)
[0465] To a reaction flask, Int H-1 (10.50 g, 41.17 mmol), allyl bromide (14.94 g, 123.51 mmol), tert-butylammonium hydrogen sulfate (2.10 g, 6.18 mmol), and KOH (4.39 g, 78.23 mmol) were added. The mixture was maintained at 25°C under nitrogen atmosphere without solvent for 16 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (150 ml x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase: EA:PE = 5:95) and dried to obtain compound Int H-2 (11.87 g).
[0466] Step 2: Synthesis of 4-methylene-6-(trifluoromethyl)isochroman (Compound Int H-3)
[0467] To a reaction flask, Int H-2 (11.87 g, 40.22 mmol), DMF (100 mL), PPh3 (3.17 g, 12.07 mmol), and Cs2CO3 (15.73 g, 48.27 mmol) were added and stirred thoroughly. Pd(OAc)2 (903 mg, 4.02 mmol) was then added. The mixture was stirred under nitrogen at 90°C for 16 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (80 mL x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase EA:PE = 5:95) and dried to afford compound Int H-3 (6.5 g).
[0468] Step 3: Synthesis of 6-(trifluoromethyl)isochroman-4-one (Compound Int H-4)
[0469] To a reaction flask, Int H-3 (6 g, 28.01 mmol), 1,4-dioxane (75 mL), and H₂O (75 mL) were added, stirred, and cooled in an ice-water bath. NaIO₄ (17.98 g, 84.04 mmol) was added, stirred for 5 minutes, and then K₂OsO₄·2H₂O (516 mg, 1.40 mmol) was added. The reaction was allowed to react at 0°C for 3 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (80 mL x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase: EA:PE = 15:85) and dried to afford compound Int H-4 (4.65 g).
[0470] Step 4: Synthesis of 6-(trifluoromethyl)isochroman-4-ol (Compound Int H-5)
[0471] Int H-4 (4.65 g, 21.51 mmol) and MeOH (80 mL) were added to a reaction flask. After dissolution, the mixture was cooled in an ice-water bath. NaBH4 (1.06 g, 27.97 mmol) was then added under nitrogen protection and allowed to react at 0°C for 1 hour. After completion of the reaction, the reaction mixture was quenched with water and the solvent was concentrated to dryness under reduced pressure. The mixture was diluted with water and extracted with ethyl acetate (60 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield compound Int H-5 (4.5 g). MS (ESI, m / z): 201.1 [M+H-18] + .
[0472] Step 5: Synthesis of 6-(trifluoromethyl)isochroman-4-yl 4-methylbenzenesulfonate (Compound Int H-6)
[0473] Compound Int H-5 (4.7 g, 21.54 mmol), TsCl (4.52 g, 23.70 mmol), DCM (100 mL), DMAP (131 mg, 1.08 mmol), and TEA (5.45 g, 53.86 mmol) were added to a reaction flask under nitrogen atmosphere and reacted at 25°C for 30 min. After completion of the reaction, the reaction solution was diluted with water and extracted with DCM (80 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield compound Int H-6 (8.3 g). MS (ESI, m / z): 390.2 [M+18] + .
[0474] Step 6: Synthesis of 1-(6-(trifluoromethyl)isochroman-4-yl)triazine (Compound Int H-7)
[0475] Int H-6 (8.3 g, 22.29 mmol), NaN3 (2.17 g, 33.44 mmol), and acetone (150 mL) were added to a reaction flask under nitrogen protection and reacted at 40°C for 16 hours. After completion of the reaction, the reaction solution was diluted with water and extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase EA:PE = 10:90) and dried to obtain compound Int H-7 (5.2 g).
[0476] Step 7: Synthesis of 6-(trifluoromethyl)isochroman-4-amine (Compound Int H-8)
[0477] Int H-7 (5.4 g, 22.21 mmol), Pd / C (2.70 g, 22.21 mmol), and MeOH (100 mL) were added to the reaction flask, replaced with a hydrogen balloon, and allowed to react at 25°C for 3 hours. After the reaction was completed, the reaction solution was directly filtered through a pad of Celite. The filter cake was washed with MeOH, and the filtrate was collected and concentrated under reduced pressure to obtain compound Int H-8 (4.6 g). MS (ESI, m / z): 218.1 [M+H] + .
[0478] Step 8: Synthesis of tert-butyl (6-(trifluoromethyl)isochroman-4-yl)carbamate (Compound Int H-9)
[0479] Int H-8 (4.6 g, 21.18 mmol), TEA (2.57 g, 25.42 mmol), and di-tert-butyl dicarbonate (4.62 g, 21.18 mmol) were added to DCM (200 mL) and stirred at room temperature overnight. After the reaction was completed, the reaction solution was diluted with water and extracted with DCM (80 ml x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase EA:PE = 10:90) and dried to obtain compound Int H-9 (4.65 g). MS (ESI, m / z): 262.1 [M+H-56] + .
[0480] Step 9: Synthesis of tert-butyl (6-(trifluoromethyl)isochroman-4-yl)carbamate (Compound Int H-10)
[0481] Int H-9 (4.65 g, 14.65 mmol) and THF (120 mL) were added to the reaction flask under nitrogen protection and cooled in an ice-water bath. NaH (879.29 mg, 21.98 mmol) was then added. The reaction was allowed to react at 0°C for 30 min, followed by the addition of CH3I (2.39 g, 16.85 mmol, 1.05 mL). The temperature was naturally raised to room temperature and the reaction was allowed to proceed for 16 hr. After the reaction was completed, the reaction solution was diluted with water and extracted with ethyl acetate (70 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield compound Int H-10 (4.5 g). MS (ESI, m / z): 276.1 [M-56]. + .
[0482] Step 10: Synthesis of N-methyl-6-(trifluoromethyl)isochroman-4-amine (Compound Int H)
[0483] To the reaction flask, Int H-10 (4.5 g, 13.58 mmol), a 4M HCl solution in 1,4-dioxane (25 mL), and DCM (50 mL) were added. The mixture was stirred at 25°C for 2 hours under nitrogen. After completion of the reaction, the mixture was concentrated under reduced pressure to obtain the crude product. The mixture was diluted with saturated sodium bicarbonate solution and extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound Int H (3 g, 12.98 mmol). MS (ESI, m / z): 232.1 [M+H] + .
[0484] Step 11: Synthesis of (R)-N-methyl-6-(trifluoromethyl)isochroman-4-amine (Compound Int H-peak 1) and (S)-N-methyl-6-(trifluoromethyl)isochroman-4-amine (Compound Int H-peak 2)
[0485] Int H was separated by SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); mobile phase: phase A: n-hexane, phase B: ethanol (0.1% isopropylamine), elution gradient: A%:B%=100%:0%, isocratic elution mode) to give (R)-N-methyl-6-(trifluoromethyl)isochroman-4-amine (compound Int H-peak 1) (retention time 1.889 min, 93.8% ee) and (S)-N-methyl-6-(trifluoromethyl)isochroman-4-amine (compound Int H-peak 2) (retention time 2.226 min, 98.9% ee).
[0486] Compound Int H-Peak 1:1 H NMR(400MHz,CD3OD)δ7.48-7.58(m,2H),7.40(s,1H),4.90(s,1H),4.70-4.78(m,1H), 4.17(dd,J=12.0,2.4Hz,1H), 3.82(dd,J=12.0,2.8Hz,1H), 3.61(s,1H), 2.43(s,3H).
[0487] Compound Int H-Peak 2: 1 H NMR(400MHz,CD3OD)δ7.48-7.58(m,2H),7.40(s,1H),4.90(s,1H),4.70-4.77(m,1H), 4.17(dd,J=12.0,2.4Hz,1H), 3.82(dd,J=12.0,2.8Hz,1H), 3.61(s,1H), 2.43(s,3H).
[0488] Intermediate Int I: 7-chloro-4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]quinoxaline-8-carboxylic acid (Int I)
[0489] Step 1: Synthesis of N-(4-bromo-5-chloro-2-fluorophenyl)-1H-imidazole-5-carboxamide (Compound Int I-2)
[0490] Int A-1 (2.50 g, 22.28 mmol) was dissolved in anhydrous DMF (50 mL) under an ice-water bath. DIPEA (8.64 g, 66.83 mmol) was slowly added dropwise. After stirring, a solution of HATU (16.94 g, 44.55 mmol) in anhydrous DMF was added dropwise. Stirring was continued for 1 hour. Finally, a solution of Int I-1 (5.0 g, 22.28 mmol) in anhydrous DMF was added dropwise. The temperature was naturally raised to 80°C and the reaction was allowed to proceed for 16 hours. After the reaction, water was added and stirred. The mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase PE:EA = 24:76) to obtain compound Int I-2 (3.94 g). MS (ESI, m / z): 317.9 [M+H] + .
[0491] Step 2: Synthesis of 8-bromo-7-chloroimidazo[1,5-a]quinoxalin-4(5H)-one (Compound Int I-3)
[0492] Int I-2 (3.94 g, 12.37 mmol) was dissolved in anhydrous DMAc (40 mL). Sodium hydride (742.16 mg, 18.55 mmol) was added portionwise under ice-cooling. The mixture was stirred for 10 minutes and then reacted at 140°C for 48 hours. After completion of the reaction, the mixture was cooled to room temperature, stirred with water, and extracted with ethyl acetate, concentrated to yield compound Int I-3 (2.59 g). MS (ESI, m / z): 298.0 [M+H] + .
[0493] Step 3: Synthesis of 8-bromo-7-chloro-N-(2,4-dimethoxybenzyl)imidazo[1,5-a]quinoxaline-4-amine (Compound Int I-4)
[0494] In anhydrous DMF (20 mL) was added with Int I-3 (2.59 g, 8.68 mmol) and PyBOP (9.03 g, 17.35 mmol) under ice. DIPEA (3.36 g, 26.03 mmol) was then added dropwise and stirred for 10 min. Finally, Int A-6 (4.35 g, 26.03 mmol) was added and the mixture was allowed to react at 60°C for 16 hr. After completion of the reaction, water was added and stirred, followed by extraction with ethyl acetate and concentration to obtain a crude product. The crude product was purified by reverse-phase HPLC column chromatography (mobile phase: H2O:ACN = 20:80) to obtain compound Int I-4 (1.00 g). MS (ESI, m / z): 447.1 [M+H] + .
[0495] Step 4: Synthesis of methyl 7-chloro-4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]quinoxaline-8-carboxylate (Compound Int I-5)
[0496] Int I-4 (1.00 g, 2.23 mmol), TEA (678.05 mg, 6.70 mmol), and Pd(dppf)2Cl2 (163.43 mg, 223.36 μmol) were added to an autoclave and dissolved in methanol (30 mL). After carbon monoxide substitution, the pressure was increased to 1.2 atm and the reaction was continued at 120°C for 16 hours. After completion of the reaction, the temperature was cooled to room temperature and the reaction was concentrated to obtain compound Int I-5 (950 mg). MS (ESI, m / z): 427.2 [M+H] + .
[0497] Step 5: Synthesis of 7-chloro-4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]quinoxaline-8-carboxylic acid (Compound Int I)
[0498] Int I-5 (950 mg, 2.23 mmol) was dissolved in methanol (30 mL) under ice-cooling. A solution of sodium hydroxide (267.07 mg, 6.68 mmol) in water (4 mL) was added dropwise. The mixture was allowed to react at 55°C for 3 hours. After completion of the reaction, dilute hydrochloric acid was added dropwise under ice-water bath until the solution became acidic. The solution was concentrated to obtain the crude product, which was then purified by reverse-phase HPLC column chromatography (mobile phase: H2O:ACN = 44:56) to obtain compound Int I (200 mg). MS (ESI, m / z): 413.0 [M+H] + .
[0499] Intermediate Int J: 7-Fluoro-4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]quinoxaline-8-carboxylic acid (Int J)
[0500] Step 1: Synthesis of N-(4-bromo-2,5-difluorophenyl)-1H-imidazole-5-carboxamide (Compound Int J-2)
[0501] Int A-1 (2.69 g, 24.04 μg) was dissolved in anhydrous DMF (150 mL) under an ice-water bath. DIPEA (4.66 g, 36.06 mmol) was slowly added dropwise. After stirring, HATU (10.97 g, 28.85 mmol) was added and stirring continued for 1 hour. Finally, Int J-1 (5 g, 24.04 μg) was added and the temperature was raised to 60°C for 48 hours. After the reaction, water was added and stirred. The mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase PE:EA = 63:37) to obtain compound Int J-2 (6.0 g). MS (ESI, m / z): 302.0 [M+H] + .
[0502] Step 2: Synthesis of 8-bromo-7-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one (Compound Int J-3)
[0503] Int J-2 (6.0 g, 19.86 mmol) was dissolved in anhydrous DMAc (100 mL). Sodium hydride (1.19 g, 29.79 mmol) was added portionwise under ice-cooling. The mixture was stirred for 10 minutes and then heated to 140°C for 72 hours. After completion of the reaction, the mixture was cooled to room temperature, stirred with water, extracted with ethyl acetate, and concentrated. The mixture was then separated and purified by reverse-phase column chromatography (H2O [0.05% ammonium bicarbonate]:MeCN = 72:28) to obtain compound Int J-3 (0.5 g). MS (ESI, m / z): 282.0 [M+H] + .
[0504] Step 3: Synthesis of 8-bromo-N-(2,4-dimethoxybenzyl)-7-fluoroimidazo[1,5-a]quinoxaline-4-amine (Compound Int J-4)
[0505] In anhydrous DMF (30 mL) was added with Int J-3 (380 mg, 1.35 mmol) and PyBOP (1.05 g, 2.02 mmol) under ice. DIPEA (522.33 mg, 4.04 mmol) was then added dropwise and stirred for 10 min. Finally, Int A-6 (337.88 mg, 2.02 mmol) was added and the mixture was allowed to react at 60°C for 16 hr. After completion of the reaction, water was added and stirred. The mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by reverse-phase column chromatography (mobile phase: H2O:ACN = 36:64) to obtain compound Int J-4 (0.50 g). MS (ESI, m / z): 431.1 [M+H] + .
[0506] Step 4: Synthesis of methyl 4-((2,4-dimethoxybenzyl)amino)-7-fluoroimidazo[1,5-a]quinoxaline-8-carboxylate (Compound Int J-5)
[0507] Int J-4 (0.50 g, 1.16 mmol), TEA (351.96 mg, 3.48 mmol), and Pd(dppf)2Cl2 (93.98 mg, 115.94 μmol) were added to an autoclave and dissolved in methanol (20 mL). After carbon monoxide substitution, the pressure was increased to 1.2 MPa and the reaction was continued at 120°C for 6 hours. After completion of the reaction, the temperature was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain compound Int J-5 (70 mg). MS (ESI, m / z): 411.1 [M+H] + .
[0508] Step 5: Synthesis of 4-((2,4-dimethoxybenzyl)amino)-7-fluoroimidazo[1,5-a]quinoxaline-8-carboxylic acid (Compound Int J)
[0509] Int J-5 (400 mg, 974.66 μmol) was dissolved in ethanol (10 mL) and H₂O (2 mL). Sodium hydroxide (77.97 mg, 1.95 mmol) was added and the reaction was heated to 90°C for 2 hours. After completion of the reaction, the solvent was removed by concentration under reduced pressure and the mixture was purified by reverse-phase column chromatography (mobile phase: H₂O [0.05% formic acid]:ACN = 65:35) to obtain compound Int J (320 mg). MS (ESI, m / z): 397.1 [M+H] + .
[0510] Intermediate Int K: 4-aminoimidazo[1,5-a]pyrido[3,4-e]pyrazine-8-carboxylic acid (Int K)
[0511] Step 1: Synthesis of N-(4,6-dichloropyridin-3-yl)-1H-imidazole-5-carboxamide (Compound Int K-3)
[0512] Compound Int K-1 (8 g, 49.08 mmol) was dissolved in anhydrous THF (100 mL). The mixture was cooled to -10°C and NaHDMS (2 M, 49.08 mL, 98.16 mmol) was added. After the addition, the mixture was stirred at -10°C for 1 hour. Then, a THF solution (100 mL) of Int K-2 (5.77 g, 24.54 mmol) was added. The mixture was warmed to 25°C and the reaction was continued for 2 hours. After completion, the reaction was quenched with an appropriate amount of acetic acid, concentrated under reduced pressure, and then added with saturated aqueous sodium bicarbonate. The solid product was collected by filtration, washed with water and hexane, and dried to obtain compound Int K-3 (10 g). MS (ESI, m / z): 257.0 [M+H] + .
[0513] Step 2: Synthesis of 8-chloroimidazo[1,5-a]pyrido[3,4-e]pyrazin-4(5H)-one (Compound Int K-4)
[0514] Compound Int K-3 (10 g, 38.90 mmol) was dissolved in anhydrous DMF (100 mL), and DBU (17.77 g, 116.70 mmol) was added. The temperature was raised to 160°C and the reaction was allowed to proceed for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, concentrated under reduced pressure, added with water, and dissolved in saturated aqueous ammonium chloride. The mixture was filtered, washed with water, and the filter cake was collected, dried, and concentrated to obtain compound Int K-4 (8 g). MS (ESI, m / z): 221.0 [M+H] + .
[0515] Step 3: Synthesis of 8-chloro-N-(2,4-dimethoxybenzyl)imidazo[1,5-a]pyrido[3,4-e]pyrazin-4-amine (Compound Int K-5)
[0516] Compound Int K-4 (5 g, 22.66 mmol), DIPEA (4.39 g, 34.00 mmol), and Int A-6 (5.68 g, 34.00 mmol) were dissolved in anhydrous DMF (300 mL). PyBOP (12.97 g, 24.93 mmol) was added portionwise with stirring. The temperature was raised to 60°C and the reaction was allowed to react for 5 hours. After completion of the reaction, the mixture was diluted with water, extracted with EA, and concentrated to obtain a crude product. The crude product was purified by reverse-phase column chromatography (mobile phase: H2O (0.05% ammonium bicarbonate): ACN = 36:64) to obtain compound Int K-5 (4.5 g). MS (ESI, m / z): 370.1 [M+H] + .
[0517] Step 4: Synthesis of methyl 4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]pyrido[3,4-e]pyrazine-8-carboxylate (Compound Int K-6)
[0518] Compound Int K-5 (4.50 g, 12.17 mmol), TEA (3.69 g, 36.51 mmol), and Pd(dppf)Cl2·DCM (986.37 mg, 1.22 mmol) were added to an autoclave and dissolved in methanol (20 mL). After carbon monoxide substitution, the pressure was increased to 1.2 MPa and the temperature was raised to 120°C for 12 hours. After completion of the reaction, the temperature was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain compound Int K-6 (4.7 g). MS (ESI, m / z): 394.1 [M+H] + .
[0519] Step 5: Synthesis of 4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]pyrido[3,4-e]pyrazine-8-carboxylic acid (Compound Int K-7)
[0520] Compound Int K-6 (4.7 g, 11.95 mmol) was dissolved in methanol (150 mL) and H₂O (30 mL). Sodium hydroxide (955.78 mg, 23.89 mmol) was added and the mixture was heated to 60°C for 3 hours. After completion of the reaction, the mixture was concentrated under reduced pressure to remove the methanol, diluted with a small amount of water, and the pH was adjusted to approximately 6 with 1N hydrochloric acid. A solid precipitated, which was filtered, washed with water, and dried to obtain compound Int K-7 (4.3 g). MS (ESI, m / z): 380.2 [M+H] + .
[0521] Step 6: Synthesis of 4-aminoimidazo[1,5-a]pyrido[3,4-e]pyrazine-8-carboxylic acid (Compound Int K)
[0522] Compound Int K-7 (4.3 g, 3.78 mmol) was dissolved in TFA (80 mL) and the temperature was raised to 90°C for 2 hours. After completion of the reaction, the solvent was removed by concentration under reduced pressure to obtain compound Int K (3.8 g). MS (ESI, m / z): 230.0 [M+H] + .
[0523] Intermediate Int L: 6-aminoimidazo[1,5-a]pyrido[3,2-e]pyrazine-2-carboxylic acid (Int L)
[0524] Step 1: Synthesis of N-(2,6-dichloropyridin-3-yl)-1H-imidazole-5-carboxamide (Compound Int L-2)
[0525] Int L-1 (5.1 g, 31.29 mmol) was dissolved in anhydrous THF (100 mL). The mixture was cooled to -10°C and NaHDMS (2.0 M, 31.29 mL, 62.57 mmol) was added. After the addition, the mixture was stirred at -10°C for 1 hour. Then, a THF solution (50 mL) of Int K-2 (2.94 g, 15.64 mmol) was added. After the addition, the mixture was heated to 25°C and the reaction was continued for 2 hours. After completion, an appropriate amount of acetic acid was added to quench the reaction. The mixture was concentrated under reduced pressure and then added with saturated aqueous sodium bicarbonate. The solid product was collected by filtration, washed with water and hexane, and dried to obtain compound Int L-2 (4.7 g). MS (ESI, m / z): 257.0 [M+H]. + .
[0526] Step 2: Synthesis of 2-chloroimidazo[1,5-a]pyrido[3,2-e]pyrazin-6(5H)-one (Compound Int L-3)
[0527] Compound Int L-2 (14.7 g, 18.28 mmol) was dissolved in anhydrous DMAc (100 mL), and K2CO3 (7.58 g, 54.85 mmol) was added. The temperature was raised to 130°C and the reaction was allowed to proceed for 6 hours. After completion of the reaction, the mixture was cooled to room temperature, concentrated under reduced pressure, added with water, and dissolved in saturated aqueous ammonium chloride. The mixture was filtered, washed with water, and the filter cake was collected, dried, and concentrated to obtain compound Int L-3 (3.4 g). MS (ESI, m / z): 221.0 [M+H] + .
[0528] Step 3: Synthesis of 2-chloro-N-(2,4-dimethoxybenzyl)imidazo[1,5-a]pyrido[3,2-e]pyrazin-6-amine (Compound Int L-4)
[0529] Compound Int L-3 (3.4 g, 15.41 mmol), DIPEA (2.99 g, 23.12 mmol), and Int A-6 (3.87 g, 23.12 mmol) were dissolved in anhydrous DMF (200 mL). PyBOP (9.62 g, 18.49 mmol) was added portionwise with stirring. The temperature was raised to 60°C and the reaction was allowed to proceed for 16 hours. After completion of the reaction, the mixture was diluted with water, extracted with EA, and concentrated to obtain a crude product. The crude product was purified by reverse-phase column chromatography (mobile phase: H2O (0.05% ammonium bicarbonate): ACN = 36:64) to obtain compound Int L-4 (2.4 g). MS (ESI, m / z): 370.1 [M+H] + .
[0530] Step 4: Synthesis of methyl 6-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]pyrido[3,2-e]pyrazine-2-carboxylate (Compound Int L-5)
[0531] Int L-4 (2.4 g, 6.49 mmol), Pd(dppf)Cl2·DCM (526.07 mg, 648.99 μmol), and TEA (1.97 g, 19.47 mmol) were added to an autoclave and dissolved in methanol (15 mL). After carbon monoxide displacement, the pressure was increased to 1.2 MPa and the temperature was raised to 120°C for 12 hours. After completion of the reaction, the temperature was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain compound Int L-5 (2.5 g). MS (ESI, m / z): 394.1 [M+H] + .
[0532] Step 5: Synthesis of 6-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]pyrido[3,2-e]pyrazine-2-carboxylic acid (Compound Int L-6)
[0533] Compound Int L-5 (2.5 g, 6.35 mmol) was dissolved in methanol (100 mL) and H2O (20 mL). Sodium hydroxide (508.39 mg, 12.71 mmol) was added and the mixture was heated to 60°C for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure to remove the methanol. A small amount of water was added to dilute the mixture and the pH was adjusted to approximately 6 with 1N hydrochloric acid. A solid precipitated and was filtered, washed with water, and the filter cake dried to obtain compound Int L-6 (2.4 g). MS (ESI, m / z): 380.2 [M+H] + .
[0534] Step 6: Synthesis of 6-aminoimidazo[1,5-a]pyrido[3,2-e]pyrazine-2-carboxylic acid (Compound Int L)
[0535] Int L-6 (0.1 g, 263.60 μmol) was dissolved in TFA (2 mL) and the temperature was raised to 90°C for 2 hours. After completion of the reaction, the solvent was removed by concentration under reduced pressure to obtain compound Int L (90 mg). MS (ESI, m / z): 230.1 [M+H] + .
[0536] Intermediate Int M: 4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]pyrido[2,3-e]pyrazine-8-carboxylic acid (Int M)
[0537] Step 1: Synthesis of N-(5-bromo-3-chloropyridin-2-yl)-1H-imidazole-5-carboxamide (Compound Int M-3)
[0538] Int M-1 (1.75 g, 8.43 mmol) was dissolved in anhydrous THF (10 mL) under an ice-water bath. NaH (674.16 mg, 16.85 mmol) was slowly added portionwise. After stirring at room temperature for 30 min, Int M-2 (1.10 g, 8.43 mmol) was added and the mixture was allowed to warm to room temperature for 8 hr. After completion of the reaction, a small amount of water was added to quench the reaction. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 90:10) to obtain compound Int M-3 (1.00 g). MS (ESI, m / z): 300.9 [M+H] + .
[0539] Step 2: Synthesis of 8-bromoimidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one (Compound Int M-4)
[0540] Int M-3 (1.00 g, 3.32 mmol) was dissolved in anhydrous DMF (10 mL), and K2CO3 (1.38 g, 9.95 mmol) was added. The reaction was allowed to proceed at 160°C for 6 hours. After completion of the reaction, the mixture was cooled to room temperature, stirred with water, and extracted with EA, and concentrated to afford compound Int M-4 (380 mg). MS (ESI, m / z): 265.0 [M+H] + .
[0541] Step 3: Synthesis of 8-bromo-N-(2,4-dimethoxybenzyl)imidazo[1,5-a]pyrido[2,3-e]pyrazin-4-amine (Compound Int M-5)
[0542] In anhydrous DMF (10 mL) was added with Int M-4 (380 mg, 1.43 mmol) and PyBOP (392.88 mg, 2.15 mmol) under ice. DIPEA (555.84 mg, 4.30 mmol) was then added dropwise and stirred for 10 min. Finally, Int A-6 (479.41 mg, 2.87 mmol) was added and the mixture was allowed to react at 80°C for 16 hr. After completion of the reaction, water was added and stirred. The mixture was extracted with EA and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 95:5) to obtain compound Int M-5 (340 mg). MS (ESI, m / z): 414.0 [M+H] + .
[0543] Step 4: Synthesis of methyl 4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]pyrido[2,3-e]pyrazine-8-carboxylate (Compound Int M-6)
[0544] Int M-5 (340 mg, 822.8 μmol), TEA (249.15 mg, 2.46 mmol), and Pd(dppf)2Cl2 (60.06 mg, 82.08 μmol) were added to an autoclave and dissolved in methanol (30 mL). After carbon monoxide substitution, the pressure was increased to 1.2 atm and the reaction was carried out at 120°C for 16 hours. After completion of the reaction, the temperature was lowered to room temperature and concentrated to obtain a crude product. The crude product was purified by reverse-phase HPLC (mobile phase: H2O:ACN = 30:70) to obtain compound Int M-6 (250 mg). MS (ESI, m / z): 394.2 [M+H] + .
[0545] Step 5: Synthesis of 4-((2,4-dimethoxybenzyl)amino)imidazo[1,5-a]pyrido[2,3-e]pyrazine-8-carboxylic acid (Compound Int M)
[0546] Int M-6 (200 mg, 510.00 μmol) was dissolved in methanol (10 mL) under ice-cooling. A 2 mL aqueous solution of sodium hydroxide (81.34 mg, 2.04 mmol) was added dropwise. The mixture was allowed to react at 60°C for 3 hours. After the reaction, the methanol was dried by spin-drying. Dilute hydrochloric acid was added dropwise to the remaining portion under ice-cooling until the solution became acidic. The mixture was filtered with suction, and the filter cake was washed twice with water to obtain compound Int M (190.00 mg). MS (ESI, m / z): 380.2 [M+H] + .
[0547] Intermediate Int N: 4-amino-9-fluoroimidazo[1,5-a]quinoxaline-8-carboxylic acid (Int N)
[0548] Step 1: Synthesis of N-(4-bromo-2,3-difluorophenyl)-1H-imidazole-5-carboxamide (Compound Int N-2)
[0549] Int N-1 (2 g, 9.62 mmol) was dissolved in anhydrous THF (10 mL) under an ice-water bath. NaH (1.54 g, 38.46 mmol) was slowly added portionwise. After stirring at room temperature for 15 minutes, Int K-2 (2.89 g, 11.54 mmol) was added and the temperature was raised to 60°C for 16 hours. After the reaction, water was added and stirred. The mixture was extracted with EA and concentrated to yield compound Int N-2 (1.50 g). MS (ESI, m / z): 302.0 [M+H] + .
[0550] Step 2: Synthesis of 8-bromo-9-fluoroimidazo[1,5-a]quinoxaline-4(5H)-one (Compound Int N-3)
[0551] Dissolve Int N-2 (1.50 g, 4.97 mmol) in anhydrous DMF (10 mL), add K2CO3 (2.06 g, 14.90 mmol), and react at 160°C for 4 hours. After completion of the reaction, cool to room temperature, add water, stir, and precipitate a solid, which is filtered to obtain compound Int N-3 (1.00 g). MS (ESI, m / z): 282.0 [M+H] + .
[0552] Step 3: Synthesis of 8-bromo-N-(2,4-dimethoxybenzyl)-9-fluoroimidazo[1,5-a]quinoxaline-4-amine (Compound Int N-4)
[0553] In anhydrous DMF (10 mL) was added with Int N-3 (400 mg, 1.42 mmol) and PyBOP (1.11 g, 2.13 mmol) under an ice bath. DIPEA (549.82 mg, 4.25 mmol) was then added dropwise and stirred for 10 min. Finally, Int A-6 (474.21 mg, 2.84 mmol) was added and the mixture was allowed to react at 60°C for 16 hr. After completion of the reaction, water was added and stirred. The mixture was extracted with EA and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 97:3) to obtain compound Int N-4 (294 mg). MS (ESI, m / z): 431.0 [M+H] + .
[0554] Step 4: Synthesis of methyl 4-((2,4-dimethoxybenzyl)amino)-9-fluoroimidazo[1,5-a]quinoxaline-8-carboxylate (Compound Int N-5)
[0555] Int N-4 (294 mg, 681.73 μmol), TEA (206.95 mg, 2.05 mmol), and Pd(dppf)2Cl2 (55.26 mg, 68.17 μmol) were added to an autoclave and dissolved in methanol (25 mL). After carbon monoxide displacement, the pressure was increased to 1.2 atm and the reaction was carried out at 120°C for 5 hours. After completion of the reaction, the temperature was cooled to room temperature and concentrated to obtain a crude product. The crude product was purified by reverse-phase HPLC (mobile phase: H2O:ACN = 30:70) to obtain compound Int N-5 (212 mg). MS (ESI, m / z): 411.2 [M+H] + .
[0556] Step 5: Synthesis of 4-((2,4-dimethoxybenzyl)amino)-9-fluoroimidazo[1,5-a]quinoxaline-8-carboxylic acid (Compound Int N-6)
[0557] Compound Int N-5 (212 mg, 516.57 μmol) was dissolved in methanol (10 mL) under ice-cooling. A 2 mL aqueous solution of sodium hydroxide (82.65 mg, 2.07 mmol) was added dropwise. The mixture was allowed to react at 55°C for 3 hours. After the reaction, the methanol was evaporated and dilute hydrochloric acid was added dropwise to the remaining portion under ice-cooling until the solution became acidic. The mixture was filtered and the filter cake was washed twice with water to obtain compound Int N-6 (200.00 mg). MS (ESI, m / z): 397.1 [M+H] + .
[0558] Step 6: Synthesis of 4-amino-9-fluoroimidazo[1,5-a]quinoxaline-8-carboxylic acid (Compound Int N)
[0559] Int N-6 (200 mg, 504.58 μmol) was added to TFA (10 mL) under ice-cooling and reacted at 80°C for 2 hours. After the reaction, the TFA was evaporated to obtain compound Int N (120 mg). MS (ESI, m / z): 247.2 [M+H] + .
[0560] Example 1: (R)-5-amino-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-c]quinazoline-9-carboxamide
[0561] Step 1: Synthesis of (R)-5-(bis(4-methoxybenzyl)amino)-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-c]quinazoline-9-carboxamide (Compound 1-1)
[0562] To a reaction flask, Int B (30 mg, 51.23 μmol), Int C (15 mg, 51.23 μmol), HATU (24 mg, 61.47 μmol), and DMF (2 mL) were added and stirred to dissolve. DIPEA (10 mg, 76.84 μmol) was then added. The mixture was reacted at 25°C under nitrogen for 2 hours. After completion of the reaction, the reaction solution was diluted with water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by scraping on a silica gel plate (developing solvent: DCM:MeOH = 10:1) to obtain compound 1-1 (13 mg).
[0563] Step 2: Synthesis of (R)-5-amino-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-c]quinazoline-9-carboxamide (Compound 1)
[0564] Compound 1-1 (13 mg, 17.74 μmol) and TFA (3 mL) were added to the reaction flask under nitrogen protection and reacted at 90°C for 5 hours. After completion of the reaction, the reaction solution was spin-dried, diluted with saturated NaHCO3 solution, and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by Pre-HPLC to obtain compound 1. MS (ESI, m / z): 493.2 [M+H] + .
[0565] 1 H NMR (400MHz, DMSO-d6) δ8.86–8.78(m,3H),8.64(s,1H),8.22–8.08(m,2H),7.94–7.74(m,3H),7.58(d,J=8.0Hz, 2H), 7.46–7.37 (m, 2H), 5.52–5.35 (m, 1H), 4.92 (d, J = 17.2Hz, 1H), 4.57 (d, J = 16.8Hz, 1H), 1.62 (d, J = 7.2Hz, 3H).
[0566] Example 2: 5-amino-N-isobutyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-c]quinazoline-9-carboxamide
[0567] Step 1: Synthesis of 5-(bis(4-methoxybenzyl)amino)-N-isobutyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-c]quinazoline-9-carboxamide (Compound 2-2)
[0568] To the reaction flask, Int B (30 mg, 51.23 μmol), 2-1 (12 mg, 51.23 μmol), HATU (24 mg, 61.47 μmol), and DMF (2 mL) were added. After stirring and dissolving, DIPEA (10 mg, 76.84 μmol) was added. The mixture was kept under nitrogen at 25°C for 2 hours. After completion of the reaction, the reaction solution was diluted with water and extracted with ethyl acetate (30 ml x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 97:3) to obtain compound 2-2 (20 mg). MS (ESI, m / z): 683.3 [M+H] + .
[0569] Step 2: Synthesis of 5-amino-N-isobutyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-c]quinazoline-9-carboxamide (Compound 2)
[0570] 2-2 (20 mg, 29.29 μmol) and TFA (3 mL) were added to the reaction flask under nitrogen protection and reacted at 90°C for 5 hours. After the reaction was completed, the reaction solution was spin-dried, diluted with saturated NaHCO3 solution, and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by Pre-HPLC to obtain compound 2. MS (ESI, m / z): 443.2 [M+H] + .
[0571] 1 H NMR (400MHz, DMSO-d6) δ8.99(s,1H),8.62(d,J=8.4Hz,1H),8.19(d,J=25.2Hz,1H),8.03(d,J=25.2Hz,1H),7.85– 7.63(m,3H),7.49–7.24(m,3H),4.89–4.73(m,2H),3.27(d,J=7.2Hz,2H),2.08(br,1H),0.94(s,3H),0.70(s,3H).
[0572] Example 3: (R)-4-amino-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0573] Step 1: Synthesis of (R)-4-((2,4-dimethoxybenzyl)amino)-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 3-1)
[0574] Int A (50 mg, 132.14 μmol) and Int C (31.08 mg, 110.12 μmol) were dissolved in anhydrous DMF (2 mL) under ice-water bath. HATU (62.81 mg, 165.18 μmol) was added with stirring, followed by dropwise addition of DIPEA (42.70 mg, 330.36 μmol). The mixture was allowed to react at 25°C for 5 hours. After completion of the reaction, water was added with stirring, and the mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 92:8) to obtain compound 3-1 (43.00 mg). MS (ESI, m / z): 643.3 [M+H] + .
[0575] Step 2: Synthesis of (R)-4-amino-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 3)
[0576] Compound 3-1 (43 mg, 66.91 μmol) was dissolved in a mixture of TFA (5 mL) and methanol (1 mL) and reacted at 100°C for 2 hours. After completion of the reaction, the mixture was washed with saturated sodium bicarbonate solution until neutral, extracted with ethyl acetate, and concentrated. The crude product was purified by reverse-phase HPLC to yield compound 3 (4.0 mg). MS (ESI, m / z): 493.3 [M+H] + .
[0577] 1 H NMR(400MHz, DMSO-d6)δ9.16(s,1H),8.85(s,1H),8.79(d,J=4.9Hz,2H),8.39(s,1H),8.11(d,J=7.9Hz,1H),7.92(s,1H),7.63–7.5 3(m,2H),7.45(dt,J=9.7,6.6Hz,4H),5.45(t,J=12.3Hz,1H),4.93(d,J=17.0Hz,1H),4.57(d,J=16.8Hz,1H),1.64(d,J=6.5Hz,3H).
[0578] The following compounds were prepared by the method and general steps described in Reference Example 3. The other required raw materials can be purchased commercially or synthesized by experienced synthesizers in the field of organic synthesis using conventional reactions from commercially purchased reagents.
[0579] Example 32: (S)-4-amino-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0580] Step 1: Synthesis of (S)-4-((2,4-dimethoxybenzyl)amino)-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 31-1)
[0581] Int A (45 mg, 118.93 μmol) and Int H-peak 2 compound (27.50 mg, 118.93 μmol) were dissolved in anhydrous DMF (2 mL) under ice-water bath. HATU (54.26 mg, 142.71 μmol) was added with stirring, followed by dropwise addition of DIPEA (23.06 mg, 178.39 μmol). The mixture was reacted at 60°C for 5 hours. After completion of the reaction, water was added with stirring, and the mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 97:3) to obtain compound 31-1 (40.0 mg). MS (ESI, m / z): 592.2 [M+H] + .
[0582] Step 2: Synthesis of (S)-4-amino-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 31)
[0583] Compound 31-1 (40 mg, 67.62 μmol) was dissolved in TFA (2 mL) and reacted at 80°C for 2 hours. After completion of the reaction, the mixture was washed with saturated sodium bicarbonate solution until neutral, extracted with ethyl acetate, and concentrated. The crude product was purified by reverse-phase HPLC to yield compound 31 (12.51 mg). MS (ESI, m / z): 442.0 [M+H] + .
[0584] 1H NMR (400MHz, DMSO-d6) δ9.26–9.16(m,1H),8.41–8.34(m,1H),7.92(s,1H),7.72–7.42(m,7H),5.81–4.62(m,3H),4.22–4.07(m,2H),2.76(s,3H).
[0585] Example 33: (R)-4-amino-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0586] Step 1: Synthesis of (R)-4-((2,4-dimethoxybenzyl)amino)-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 32-1)
[0587] Int A (45 mg, 118.93 μmol) and Int H-peak 1 compound (27.50 mg, 118.93 μmol) were dissolved in anhydrous DMF (2 mL) under ice-water bath. HATU (54.26 mg, 142.71 μmol) was added with stirring, followed by dropwise addition of DIPEA (23.06 mg, 178.39 μmol). The mixture was reacted at 60°C for 5 hours. After completion of the reaction, water was added with stirring, and the mixture was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 97:3) to obtain compound 32-1 (30.0 mg). MS (ESI, m / z): 592.2 [M+H] + .
[0588] Step 2: Synthesis of (R)-4-amino-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 32)
[0589] Compound 32-1 (25 mg, 41.77 μmol) was dissolved in TFA (2 mL) and reacted at 80°C for 2 hours. After completion of the reaction, the mixture was washed with saturated sodium bicarbonate solution until neutral, extracted with ethyl acetate, and concentrated. The crude product was purified by reverse-phase HPLC to obtain compound 32 (7.71 mg). MS (ESI, m / z): 442.0 [M+H] + .
[0590] 1H NMR (400MHz, DMSO) δ9.25–9.16(m,1H),8.41–8.34(m,1H),7.91(s,1H),7.71–7.39(m,7H),5.81–4.62(m,3H),4.22–4.07(m,2H),2.76(s,3H).
[0591] Example 34: (S)-4-amino-7-fluoro-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0592] Step 1: Synthesis of 4-amino-7-fluoroimidazo[1,5-a]quinoxaline-8-carboxylic acid (Compound 33-1)
[0593] Dissolve Int J (1.5 g, 3.78 mmol) in TFA (20 mL) and heat to 90°C for 2 hours. After completion of the reaction, concentrate under reduced pressure to remove the solvent to obtain compound 33-1 (1.35 g). MS (ESI, m / z): 247.0 [M+H] + .
[0594] Step 2: Synthesis of (S)-4-amino-7-fluoro-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 33)
[0595] 33-1 (1.35 g, 3.75 mmol) and Int E (950.60 mg, 3.75 mmol) were dissolved in anhydrous NMP (20 mL). DIPEA (2.42 g, 18.74 mmol) and HATU (1.71 g, 4.50 mmol) were added, and the reaction system was allowed to react at 25°C for 2 hours. After completion, the reaction was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The crude product was isolated and purified by silica gel column chromatography (DCM:MeOH = 93:7) and then by reverse-phase column chromatography (mobile phase: H2O (0.05% ammonium bicarbonate):ACN = 58:42) to obtain compound 33 (1.2 g). MS (ESI, m / z): 446.0 [M+H] + .
[0596] 1H NMR(400MHz,DMSO-d6)δ9.13(s,1H),8.49–8.25(m,1H),8.00–7.88(m,1H), 7.74–7.17(m,6H),6.58–5.59(m,1H),4.93–4.62(m,2H),2.73–2.59(m,3H).
[0597] Example 35: (S)-4-amino-7-chloro-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0598] Step 1: Synthesis of (S)-7-chloro-4-((2,4-dimethoxybenzyl)amino)-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 34-1)
[0599] To the reaction flask, Int E (25 mg, 96.89 μmol), Int I (40 mg, 96.89 μmol), HATU (44 mg, 116.27 μmol), and NMP (2 mL) were added and stirred to dissolve. DIPEA (19 mg, 145.34 μmol) was then added. The mixture was stirred under nitrogen and reacted at 60°C for 5 hours. After completion of the reaction, the reaction solution was diluted with water and extracted with EA (30 ml x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 97:3) to obtain compound 34-1 (36 mg). MS (ESI, m / z): 612.2 [M+H] + .
[0600] Step 2: Synthesis of (S)-4-amino-7-chloro-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 34)
[0601] DDQ (67 mg, 294.12 μmol) was added to a solution of compound 34-1 (36 mg, 58.82 μmol) in DCM (5 mL) under nitrogen atmosphere at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product. The reaction solution was spin-dried, diluted with saturated NaHCO3 solution, and extracted with EA (30 ml x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by Pre-HPLC to obtain compound 34 (14 mg). MS (ESI, m / z): 462.0 [M+H]+ .
[0602] 1 H NMR(400MHz,DMSO-d6)δ9.22–9.06(m,1H),8.60–8.29(m,1H),7.96–7.90(m,1H),7.70–7 .46(m,4H),7.38–7.23(m,2H),6.64–5.46(m,1H),4.93–4.58(m,2H),2.74–2.52(m,3H).
[0603] Example 36: (S)-4-amino-7-chloro-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0604] Step 1: Synthesis of (S)-7-chloro-4-((2,4-dimethoxybenzyl)amino)-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 36-1)
[0605] To the reaction flask were added Int H-peak 2 (22 mg, 96.89 μmol), Int I (40 mg, 96.89 μmol), HATU (44 mg, 116.27 μmol), and NMP (2 mL). After stirring and dissolving, DIPEA (19 mg, 145.34 μmol) was added. The mixture was stirred under nitrogen and reacted at 60°C for 5 hr. After completion of the reaction, the reaction solution was diluted with water and extracted with EA (30 ml x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 97:3) to obtain compound 36-1 (40 mg). MS (ESI, m / z): 626.2 [M+H] + .
[0606] Step 2: Synthesis of (S)-4-amino-7-chloro-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 36)
[0607] TFA (2 mL) and 36-1 (40 mg, 53.06 μmol) were added to the reaction flask under nitrogen atmosphere and reacted at 80°C for 2 hours. The reaction solution was spin-dried, diluted with saturated NaHCO3 solution, and extracted with EA (30 ml x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by Pre-HPLC to obtain compound 36 (14 mg). MS (ESI, m / z): 476.1 [M+H] + .
[0608] 1 H NMR(400MHz,DMSO-d6)δ9.21–9.09(m,1H),8.62–8.27(m,1H),7.95–7.91(m,1H ),7.80–7.47(m,6H),5.89–4.59(m,3H),4.22–3.99(m,2H),2.82–2.58(m,3H).
[0609] Example 37: (S)-4-amino-N-methyl-7-(trifluoromethyl)-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0610] Step 1: Synthesis of (S)-4-((2,4-dimethoxybenzyl)amino)-N-methyl-7-(trifluoromethyl)-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 38-1)
[0611] To the reaction flask, Int H-peak 2 (21 mg, 89.61 μmol), Int G (40 mg, 89.61 μmol), HATU (41 mg, 107.5 μmol), and NMP (2 mL) were added and stirred to dissolve. DIPEA (17 mg, 132.34 μmol) was then added. The mixture was stirred under nitrogen and reacted at 60°C for 1 hr. After completion of the reaction, the reaction solution was diluted with water and extracted with EA (30 ml x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 97:3) to obtain compound 38-1 (20 mg). MS (ESI, m / z): 660.2 [M+H] + .
[0612] Step 2: Synthesis of (S)-4-amino-N-methyl-7-(trifluoromethyl)-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 38)
[0613] TFA (2 mL) and 38-1 (35 mg, 53.06 μmol) were added to the reaction flask under nitrogen protection and reacted at 80°C for 2 hours. The reaction solution was spin-dried, diluted with saturated NaHCO3 solution, and extracted with EA (30 ml x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by Pre-HPLC to obtain compound 38 (16 mg). MS (ESI, m / z): 510.2 [M+H] + .
[0614] 1 H NMR(400MHz,DMSO-d6)δ9.32–9.20(m,1H),8.63–8.36(m,1H),8.03–7.94(m,1H),7.8 1–7.30(m,6H),5.83(s,1H),4.99–4.59(m,2H),4.37–3.84(m,2H),2.80–2.52(m,3H).
[0615] Example 38: (S)-6-amino-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]pyrido[3,2-e]pyrazine-2-carboxamide
[0616] Int L (80 mg, 233.09 μmol) and Int E (50.62 mg, 199.58 μmol) were dissolved in anhydrous NMP (3 mL). DIPEA (150.62 mg, 1.17 mmol) and HATU (106.29 mg, 279.71 μmol) were added, and the reaction system was incubated at 25°C for 2 hours. After completion, the reaction was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The crude product was separated and purified by Prep-HPLC to obtain Compound 48 (70 mg). MS (ESI, m / z): 429.2 [M+H] + .
[0617] 1 H NMR(400MHz,DMSO-d6)δ9.09–8.88(m,1H),8.06–7.59(m,6H),7.41–7.30(m,1H ),7.29–7.19(m,1H),6.51–6.11(m,1H),4.95–4.66(m,2H),2.94–2.61(m,3H).
[0618] Example 39: (S)-4-amino-9-fluoro-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 49)
[0619] Int N (50 mg, 203.09 μmol), Int E (51.51 mg, 203.09 μmol), and HATU (115.83 mg, 304.63 μmol) were added to NMP (8 mL), and finally DIPEA (78.74 mg, 609.27 μmol) was added dropwise. The reaction was allowed to react at 60°C for 2 hours. After completion of the reaction, water was added and stirred. The mixture was extracted with EA and concentrated to obtain the crude product, which was then purified by reverse-phase HPLC to yield compound 49 (10 mg). MS (ESI, m / z): 446.2 [M+H] + .
[0620] 1 H NMR(400MHz,DMSO-d6)δ9.09–8.60(m,1H),8.14–7.87(m,1H),7.73–7.49(m,3H ),7.47–7.10(m,4H),6.57–5.57(m,1H),5.07–4.35(m,2H),2.76–2.54(m,3H).
[0621] Example 40: (S)-4-amino-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]pyrido[2,3-e]pyrazine-8-carboxamide (Compound 50)
[0622] Step 1: Synthesis of (S)-4-((2,4-dimethoxybenzyl)amino)-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]pyrido[2,3-e]pyrazine-8-carboxamide (Compound 50-1)
[0623] Int M (100 mg, 263.60 μmol), Int E (66.86 mg, 263.60 μmol), HATU (200.57 mg, 527.20 μmol), and DIPEA (102.20 mg, 790.79 μmol) were added to NMP (10 mL) under an ice bath and reacted at 60°C for 2 hours. After completion, the reaction was stirred with water, extracted with EA, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 95:5) to obtain compound 50-1 (60 mg). MS (ESI, m / z): 579.2 [M+H] + .
[0624] Step 2: Synthesis of (S)-4-amino-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]pyrido[2,3-e]pyrazine-8-carboxamide (Compound 50)
[0625] 50-1 (60 mg, 103.71 μmol) and DDQ (47.08 mg, 207.42 μmol) were added to DCM (10 mL) and reacted at 25°C for 3 hours. After completion of the reaction, the mixture was washed with saturated sodium bicarbonate solution, extracted with EA, and concentrated to obtain a crude product, which was then purified by reverse-phase HPLC to afford compound 50 (10 mg). MS (ESI, m / z): 429.2 [M+H] + .
[0626] 1 H NMR(400MHz,DMSO-d6)δ9.23(s,1H),8.82–8.65(m,1H),8.66–8.53(m,1H),8.11–7.79(m,3H ),7.75–7.60(m,1H),7.48–7.09(m,2H),6.59–6.15(m,1H),5.03–4.41(m,2H),2.72(s,3H).
[0627] Example 41: (S)-4-amino-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]pyrido[3,4-e]pyrazine-8-carboxamide
[0628] Int K (3.5 g, 10.20 mmol) and Int E (2.59 g, 10.20 mmol) were dissolved in anhydrous NMP (100 mL). DIEA (6.59 g, 50.99 mmol) and HATU (4.65 g, 12.24 mmol) were added, and the reaction system was incubated at 25°C for 3 hours. After completion, the reaction was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The crude product was purified by silica gel column chromatography (DCM:MeOH = 92:8) and then by reverse-phase column chromatography (mobile phase: H2O (0.05% ammonium bicarbonate):ACN = 58:42) to obtain compound 47 (3.45 g). MS (ESI, m / z): 429.2 [M+H] + .
[0629] 1H NMR(400MHz,DMSO-d6)δ9.36–9.28(m,1H),8.72–8.63(m,1H),8.59–8.50(m,1H),8.02–7.96(m,1H ),7.81–7.56(m,3H),7.40–7.23(m,2H),6.49–6.00(m,1H),4.91–4.67(m,2H),2.80–2.66(m,3H).
[0630] Example 42: 4-amino-N-isobutyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0631] Step 1: Synthesis of 4-((2,4-dimethoxybenzyl)amino)-N-isobutyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 4-1)
[0632] Int A (50 mg, 132.14 μmol) was added to anhydrous THF (10 mL). Pyridine (41.81 mg, 528.57 μmol) and phosphorus oxychloride (30.39 mg, 198.21 μmol) were added dropwise in an ice bath. After stirring for 10 minutes, 2-1 (30.69 mg, 132.14 μmol) was added and the mixture was allowed to warm to room temperature for 3 hours. After completion, the reaction was quenched with water, extracted with ethyl acetate, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 95:5) to obtain compound 4-1 (10 mg). MS (ESI, m / z): 593.2 [M+H] + .
[0633] Step 2: Synthesis of 4-amino-N-isobutyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 4)
[0634] Compound 4-1 (10 mg, 16.87 μmol) was added to TFA (8 mL) and reacted at 60°C for 4 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and washed with saturated sodium bicarbonate solution until alkaline. The crude product was extracted with ethyl acetate and concentrated to obtain a crude product. The crude product was purified by reverse-phase HPLC to obtain compound 4 (3.99 mg). MS (ESI, m / z): 443.2 [M+H] + .
[0635] 1H NMR(400MHz,DMSO-d6)δ9.28–9.05(m,1H),8.98(s,1H),8.54–7.63(m,4H),7.53–7.27(m,4 H), 4.99–4.69 (m, 2H), 3.29 (d, J = 7.4Hz, 2H), 2.14–1.85 (m, 1H), 0.95 (s, 3H), 0.71 (s, 3H).
[0636] The following compounds were prepared by the method and general steps described in Reference Example 42. The other required raw materials can be purchased commercially or synthesized by experienced synthesizers in the field of organic synthesis using conventional reactions from commercially purchased reagents.
[0637] Example 44: (R)-4-amino-3-methyl-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0638] Step 1: Synthesis of (R)-4-((2,4-dimethylbenzyl)amino)-3-methyl-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 10-1)
[0639] Int D (60 mg, 137.61 μmol) was added to anhydrous THF (10 mL). Pyridine (65.31 mg, 825.67 μmol) and phosphorus oxychloride (63.30 mg, 412.84 μmol) were added dropwise in an ice bath. After stirring for 10 minutes, Int C (38.84 mg, 137.61 μmol) was added and the mixture was reacted at 60°C for 3 hours. After completion, the reaction was quenched with water, extracted with ethyl acetate, and concentrated to obtain compound 10-1 (50 mg). MS (ESI, m / z): 657.2 [M+H] + .
[0640] Step 2: Synthesis of (R)-4-amino-3-methyl-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 10)
[0641] 10-1 (50 mg, 76.14 μmol) was added to TFA (12 mL) and reacted at 100°C for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and washed with saturated sodium bicarbonate solution until alkaline. The crude product was extracted with ethyl acetate and concentrated to obtain the crude product. The crude product was purified by reverse-phase HPLC to obtain compound 10 (24.01 mg). MS (ESI, m / z): 507.2 [M+H] + .
[0642] 1 H NMR (400MHz, DMSO-d6) δ9.04(s,1H),8.86(s,1H),8.80(d,J=4.8Hz,2H),8.33(s,1H),8.12(d,J=7.6Hz,1H) ,7.71–7.15(m,4H),6.92(s,2H),5.61–5.26(m,1H),5.12–4.38(m,2H),2.65(s,3H),1.64(d,J=6.4Hz,3H).
[0643] Example 45: 4-amino-N-isobutyl-3-methyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0644] Step 1: Synthesis of 4-((2,4-dimethylbenzyl)amino)-N-isobutyl-3-methyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 11-1)
[0645] Int D (7 mg, 17.84 μmol) and DIPEA (4.61 mg, 35.68 μmol) were added to anhydrous DMF (5 mL) under ice. HATU (10.17 mg, 26.76 μmol) was slowly added. After stirring for 10 minutes, 2-1 (4.14 mg, 17.84 μmol) was added and allowed to react at 25°C for 3 hours. After completion, the reaction was quenched with water, extracted with ethyl acetate, and concentrated to afford compound 11-1 (6 mg). MS (ESI, m / z): 607.3 [M+H] + .
[0646] Step 2: Synthesis of 4-amino-N-isobutyl-3-methyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 11)
[0647] 11-1 (6 mg, 9.89 μmol) was added to TFA (10 mL) and reacted at 100°C for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and washed with saturated sodium bicarbonate solution until alkaline. The crude product was extracted with ethyl acetate and concentrated to obtain the crude product. The crude product was purified by reverse-phase HPLC to obtain compound 11 (1.62 mg). MS (ESI, m / z): 457.2 [M+H] + .
[0648] 1 H NMR(400MHz,DMSO-d6)δ9.24–8.86(m,2H),8.43–8.08(m,2H),7.93–7.22(m,3H),6.92(d,J=8.4Hz,2H ),5.39–4.18(m,2H),3.34(d,J=7.2Hz,3H),2.68(s,2H),2.22–1.84(m,1H),1.01(s,3H),0.76(s,3H).
[0649] Example 46: (S)-4-amino-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0650] Step 1: Synthesis of (S)-4-((2,4-dimethylbenzyl)amino)-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 13-1)
[0651] Int A (84 mg, 222.00 μmol) was added to anhydrous THF (10 mL). Pyridine (105.36 mg, 1.33 mmol) and phosphorus oxychloride (136.16 mg, 887.99 μmol) were added dropwise in an ice bath. After stirring for 10 minutes, Int E hydrochloride (56.31 mg, 222.00 μmol) was added and the mixture was allowed to warm to room temperature for 16 hours. After completion, the reaction was quenched with water, extracted with ethyl acetate, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (mobile phase: DCM:MeOH = 90:10) to obtain compound 13-1 (36 mg). MS (ESI, m / z): 578.1 [M+H] + .
[0652] Step 2: Synthesis of (S)-4-amino-N-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (Compound 13)
[0653] 13-1 (10 mg, 17.31 μmol) was dissolved in dichloromethane (10 mL). DDQ (58.96 mg, 259.72 μmol) was added under ice-cooling. The temperature was naturally raised to 25°C and allowed to react for 24 hours. After completion of the reaction, the solution was spin-dried and purified by reverse-phase HPLC to obtain compound 13 (1.20 mg). MS (ESI, m / z): 428.1 [M+H] + .
[0654] 1 H NMR(400MHz,DMSO-d6)δ9.19(s,1H),8.34(s,1H),7.92(s,1H),7.64(d,J=7.6Hz,1H),7.57–7.4 0(m,4H),7.34(d,J=7.6Hz,1H),7.26(s,1H),6.50–6.28(m,1H),5.00–4.41(m,2H),2.68(s,3H).
[0655] The following compounds were prepared by the method and general steps described in Reference Example 46. The other required raw materials can be purchased commercially or synthesized by experienced synthesizers in the field of organic synthesis using conventional reactions from commercially purchased reagents.
[0656] Example 51: (S)-4-amino-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]pyrido[3,4-e]pyrazine-8-carboxamide
[0657] Step 1: Synthesis of (S)-4-((2,4-dimethoxybenzyl)amino)-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]pyrido[3,4-e]pyrazine-8-carboxamide (Compound 51-1)
[0658] Int H-peak 2 (30.50 mg, 131.92 μmol) and Int K-7 (50 mg, 101.43 μmol) were dissolved in anhydrous NMP (3 mL). DIPEA (65.49 mg, 506.70 μmol) and HATU (66.43 mg, 121.61 μmol) were added, and the reaction system was incubated at 20°C for 2 hours. After completion, the reaction was diluted with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The crude product was isolated and purified by silica gel column chromatography (DCM:MeOH = 93:7) to obtain compound 51-1 (40 mg). MS (ESI, m / z): 593.3 [M+H] + .
[0659] Step 2: Synthesis of (S)-4-amino-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)imidazo[1,5-a]pyrido[3,4-e]pyrazine-8-carboxamide (Compound 51)
[0660] 51-1 (40 mg, 67.50 μmol) was dissolved in TFA (3 mL) and heated to 90°C for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure, dissolved in EA, and washed with saturated sodium bicarbonate. The organic layer was dried and concentrated, and purified by reverse-phase column chromatography (mobile phase: H2O (0.05% formic acid): ACN = 60:40) to obtain compound 51 (18 mg). MS (ESI, m / z): 443.2 [M+H] + .
[0661] 1 HNMR(400MHz,DMSO-d6)δ9.34–9.28(m,1H),8.69–8.63(m,1H),8.61–8.52(m,1H),8.01–7.96(m,1 H),7.78–7.51(m,5H),5.85–5.34(m,1H),4.95–4.65(m,2H),4.17–4.07(m,2H),2.82–2.74(m,3H).
[0662] Separation method
[0663] The Prep-HPLC purification of the compounds in the examples was performed using an Aglient 1260 or Waters 2489 HPLC, and the separation column model was a Waters SunFire Prep C 18 OBD(19mm×150mm×5.0μm), Waters Xbridge Prep C 18 OBD (19mm×150mm×5.0μm) or YMC Actus Triart C 18 (20 mm × 150 mm × 5.0 μm), the column temperature was 25°C, the detection wavelength was 214 nm, 254 nm, or 280 nm, mobile phase A was acetonitrile, mobile phase B was 0.05% formic acid aqueous solution or 0.05% ammonium bicarbonate aqueous solution or 0.05% TFA aqueous solution, the volume ratio of the mobile phase was adjusted according to the polarity of the compound; the mobile phase flow rate was 28 mL / min.
[0664] Reference Example 1:
[0665] The preparation process refers to WO2022169948A1.
[0666] Reference Example 2:
[0667] The preparation process refers to WO2022169948A1.
[0668] Reference Example 3:
[0669] The preparation process refers to WO2022169948A1.
[0670] Reference Example 4:
[0671] The preparation process refers to WO2022169948A1.
[0672] Reference Example 5:
[0673] The preparation process refers to WO2022169948A1.
[0674] Reference Example 6:
[0675] The preparation process refers to WO2022169948A1.
[0676] Biological evaluation
[0677] Experimental Example 1: Inhibitory effect of compounds on PRMT5-MTA methyltransferase activity
[0678] The prepared protein solution (PRMT5 / MEP50 (Reaction) and MTA (MCE) mixture) was preincubated with different concentrations of the test compound of the present invention (500 nM starting point, 5-fold dilution, 7 points; or 100 nM starting point, 5-fold dilution, 7 points) at 25°C for 30 min, and then the prepared substrate solution (biotinylated histone H4 peptide (Biotinylated histone H4 peptide, Sangon)) was added, and the reaction was incubated at 25°C for 90 min. After the reaction, the prepared detection reagent mixture (Protein A-Eu (Cisbio), anti-histone H4 antibody (Anti-Histone H4 antibody, Abcam), and Streptavidin-D2 (Cisbio)) was added, and the mixture was incubated at 25°C for 60 min. The fluorescence signal ratio (Ratio) was detected using a BMG microplate reader.
[0679] The solvent group (DMSO) was used as the negative control and the reaction buffer group (without PRMT5·MTA enzyme) was used as the blank control. The percentage inhibition rate of compounds at different concentrations was calculated according to the following formula:
[0680] Percent inhibition rate = (negative control Ratio - test compound Ratio) / (negative control Ratio - blank control Ratio) × 100%.
[0681] The four-parameter equation Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC 50 -X)*Hillslope)) fits the detection signal value and calculates IC 50 Where Y is the relative inhibitory activity percentage, Top and Bottom are the maximum and minimum values of the fitted curve, respectively, X is the logarithmic concentration of the compound, and Hillslope is the slope of the curve. The inhibitory effects of the compounds on PRMT5-MTA methyltransferase were determined according to the above method, and the results are shown in Table 1.
[0682] Table 1. Inhibitory activity of the compounds of the present invention against PRMT5-MTA
[0683] The experimental results show that the compounds of the present invention have a strong inhibitory effect on PRMT5-MTA enzyme.
[0684] Experimental Example 2: Inhibitory Effect of Compounds on MTAP Deleted / Parental HCT116 Cell Proliferation
[0685] MTAP-deficient / parental HCT116 cells (purchased from HORIZON) were cultured as monolayers in RPMI6140 medium (source culture) supplemented with 10% FBS and 1% P / S at 37°C and 5% CO2. Cells in logarithmically growing phase were digested and the concentration adjusted. 250 cells per well were seeded into 96-well plates and cultured overnight. Prediluted test compounds were added (5000 nM starting point, 4-fold dilution, 9 points). A negative control group received DMSO, and a blank control group received culture medium. After 8 days of incubation at 37°C and 5% CO2, 50 μl of CellTiter-Glo (Promega) was added to each well for lysis at room temperature in the dark for 10 minutes. The test solution was transferred to a 96-well opaque white plate, and the relative chemiluminescence units were read on a microplate reader in chemiluminescence detection mode.
[0686] The percentage inhibition rate of compounds at different concentrations was calculated according to the following formula:
[0687] Percent inhibition rate=(1-(chemiluminescent signal value of the test compound-chemiluminescent signal value of the blank control) / (chemiluminescent signal value of the negative control-chemiluminescent signal value of the blank control))×100%.
[0688] The percentage inhibition rate of different concentrations of compounds was plotted against the compound concentration, and the curve was fitted according to the four-parameter model to calculate the IC 50 value:
[0689] y=Min+(Max-Min) / (1+(x / IC 50 )^(-Hillslope)), where: y is the percentage inhibition rate; Max and Min are the maximum and minimum values of the fitted curve, respectively; x is the logarithmic concentration of the compound; and Hillslope is the slope of the curve.
[0690] The proliferation inhibitory activity of the compounds on MTAP-deficient / parental HCT116 cells was determined according to the above method. The results are shown in Table 2.
[0691] Table 2. Proliferation inhibitory activity of the compounds of the present invention on MTAP-deficient / parental HCT116 cells
[0692] The experimental results show that the compound of the present invention has a strong inhibitory effect on MTAP-deficient HCT116 cells and has a certain selectivity relative to MTAP parent HCT116 cells.
[0693] Experimental Example 3: Liver microsome stability test
[0694] Human liver microsomal solution was used to investigate the stability of the compounds of the present invention and reference example compounds in microsomes. The compounds of the present invention and reference example compounds were added to the liver microsomal solution and pipetted to mix, 50 μl was mixed with 25 μl PBS, and pre-incubated (37°C) for 5 min. NADPH (25 μl) was added to make the final concentration of the test compound 1 μM, the final concentration of human liver microsomal protein 0.5 mg / ml, and the incubation time was 0 and 15 minutes. After the corresponding reaction time, 300 μl of ice acetonitrile containing internal standard was added to terminate the reaction, vortexed, and temporarily stored at -80°C for testing. The LC-MS / MS method was used to detect the prototype of the test compound in the sample, and the prototype remaining rate after 15 minutes of incubation was calculated. The results of the liver microsomal stability test are shown in Table 3 below.
[0695] Table 3. Remaining rate of prototype of the compounds of the present invention and reference example compounds after incubation in human liver microsomes for 15 min
[0696] The experimental results show that the compound of the present invention is relatively stable in human liver microsomes.
[0697] Experimental Example 4: In vitro permeability test
[0698] In vitro permeability was tested using MDCK cells. Permeability experiments were performed in duplicate in a transwell system at a single concentration (2 μM) and incubated for 120 minutes. The apical to basolateral (A to B, A to B) transport and basolateral to apical (B to A, B to A) transport of the corresponding compounds were measured, and the permeation rate (apparent permeability) of the test compound was calculated (P app x 10 -6 The results of the in vitro permeability test are shown in Table 4 below.
[0699] Table 4. In vitro permeability data of the compounds of the present invention and reference examples
[0700] Note: Permeability level: Low: Papp≤0.5(×10 -6 cm / s); Moderate: 0.5<Papp<2.5(×10 -6 cm / s); High: Papp≥2.5(×10 -6 cm / s).
[0701] The test results show that the compound of the present invention has good penetration into MDCK cells.
[0702] Experimental Example 5: Biochemical hERG inhibition assay
[0703] 1. Test system:
[0704] Kit: Predictor TM hERG Fluorescence Polarization Assay,(ThermoFisher),
[0705] The kit contains:
[0706] positive control compound, hERG potassium channel blocker E4031;
[0707] hERG cell membrane;
[0708] Affinity tracer Tracer;
[0709] hERG buffer.
[0710] 2. Test parameters:
[0711] hERG concentration: 1×
[0712] Tracer concentration: 1nM
[0713] Incubation time: 2h
[0714] BMG PHERAstar FS FP
[0715] 3. Test method:
[0716] Carry out the test according to the kit instructions, the steps are as follows:
[0717] Test group: Different concentrations of the test compound were added to a microplate containing hERG cell membranes. Tracer, a tracer with high hERG affinity, was then added to each well. The microplate was incubated at room temperature for 2 hours, and the changes in fluorescence polarization (Excitation: 540 nm; Emission: 590 nm) were detected using a multifunctional microplate reader.
[0718] Positive control group: 30 μM positive control compound E4031 was used instead of the test compound, and the experimental method was the same as that of the test group.
[0719] Blank control group: hERG buffer was used instead of the test compound, and no hERG cell membrane was added. The experimental method was the same as that of the test group.
[0720] 4. Data processing:
[0721] The percentage inhibition rate of hERG by the compounds of the present invention at different concentrations was calculated according to the following formula.
[0722] Percent inhibition rate = (1-(fluorescence polarization value of the test compound-fluorescence polarization value of the positive control group) / (fluorescence polarization value of the blank control group-fluorescence polarization value of the positive control group))*100%
[0723] When the percentage inhibition rate is between 30% and 80%, the half-maximal inhibitory concentration (IC) of the compound on hERG is estimated according to the following formula: 50 ) or range:
[0724] IC 50 =X×(1-percent inhibition rate (%)) / percent inhibition rate (%), wherein: X is the test concentration of the compound when the inhibition rate is between 30-80%.
[0725] 5. Experimental results:
[0726] The hERG inhibition of the compounds was determined using the above method. The results are shown in Table 5 below.
[0727] Table 5. hERG inhibition test results
[0728] The test results showed that the compound of the present invention had no obvious hERG inhibitory activity.
[0729] Experimental Example 6: Pharmacokinetics of the compound in balb / c mice
[0730] The compound of the present invention and the reference example compound were administered intravenously (1 mg / kg) and orally (10 mg / kg). The IV vehicle was 5% DMSO + 5% Solutol + 90% Saline, and the PO vehicle was 10% Solutol + 90% H2O. Blood (40-50 μl) was collected via the eye socket at 0 h before dosing and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24, and 48 h after dosing (intravenously) and at 0 h before dosing and at 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24, and 48 h after dosing (orally). The blood was collected in K2-EDTA anticoagulant tubes and centrifuged at 4000 rpm for 10 min (4°C). Plasma was separated and stored at -80°C until assayed. A 10 μl plasma sample was added to 90 μl of acetonitrile containing an internal standard, shaken to mix, and centrifuged at 4000 rpm at 4°C for 10 minutes. The supernatant was then analyzed by LC-MS / MS. Pharmacokinetic parameters were calculated using WinNonlin 6.3 software using a non-compartmental model. The results are shown in Table 6.
[0731] Table 6: Pharmacokinetic parameters of the compounds in mice
[0732] in conclusion:
[0733] The above experimental results show that the compound of the present invention has a low clearance rate in mice, a high blood concentration and a high in vivo exposure, and has a good oral absorption effect.
[0734] In addition to those described herein, various modifications of the present invention will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including all patents, patent applications, journal articles, books, and any other disclosures) is incorporated herein by reference in its entirety.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof: in: Ring A is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aromatic rings and 5-10 membered heteroaromatic rings; R is selected from: X 1 , X 2 , X 3 Each independently selected from CR 9 and N; X 4 , X 5 are each independently selected from C and N; X 6 , X 7 , X 8 Each independently selected from CR 1 and N; is a single bond or multiple bonds; R 1 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 7 R 8 , -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 7 R 8 , -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent; R 2 For LR 2 '; L is selected from a direct bond and -(CR 5 R 6 ) p -; R 2 'Selected from hydrogen, deuterium, C 1-6 Alkyl, C 2-10 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R 12 、-OR 11 、-C(O)OR 11 、-C(O)R 12 and -C(O)NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, nitro, azido, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-10 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-10 Aryl, C 1-4 alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 7 R 8 , -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent; R 3 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 7 R 8 , -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 7 R 8 , -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 substituted by a substituent; R 4 is independently selected at each occurrence from hydrogen, deuterium, halogen, cyano, nitro, azido, oxo, C 1-6 Alkyl, C 2-10 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 7 R 8 , -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 alkyl Base-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 5 R 6 , -C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R 5 )-C(O)R 12 or, R 3 , R 4 The atoms connected to it form a 3-8 membered heterocyclic group, a 5-8 membered cycloalkyl group, a C 6-10 Aromatic rings and 5-10 membered heteroaromatic rings; R 5 and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-6 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted by an alkanoyl substituent, or, R 5 and R 6 The nitrogen atom directly connected thereto forms a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent; R 7 and R 8 are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-6 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted by an alkanoyl substituent, or, R 7 and R 8 The nitrogen atom directly connected thereto forms a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy group, 5-10 5- to 10-membered heteroaryl, amino, C 1-6 Alkyl monosubstituted amino, C 1-6 Alkyl disubstituted amino and C 1-6 substituted with an alkanoyl substituent; R 9 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 7 R 8 , -C 0-6 Alkyl-C(O)NR 7 R 8 and -C 0-6 Alkyl-N(R 7 )-C(O)R 12 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, deuterium substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-6 Alkyl-SF5, -C 0-6 Alkyl-OS(O)2R 10 , -C 0-6 Alkyl-S(O) r R 10 , -C 0-6 Alkyl-OR 11 , -C 0-6 Alkyl-C(O)OR 11 , -C 0-6 Alkyl-C(O)SR 11 , -C 0-6 Alkyl-SC(O)R 12 , -C 0-6 Alkyl-C(O)R 12 , -C 0-6 Alkyl-OC(O)R 12 , -C 0-6 Alkyl-P(O)(R 12 2. -C 0-6 Alkyl-NR 5 R 6 , -C 0-6 Alkyl-C(O)NR 5 R 6 and -C 0-6 Alkyl-N(R 5 )-C(O)R 12 substituted by a substituent; Each R 10 are independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent; Each R 11 independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent; Each R 12 are independently selected from hydrogen, deuterium, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 7 R 8 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, 3-8 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 5 R 6 substituted by a substituent; n is 0, 1, 2 or 3; p is 1 or 2; Each r is independently 0, 1 or 2.
2. The compound according to claim 1 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein: Ring A is selected from C 6-10 Aromatic rings and 5-10 membered heteroaromatic rings; R is selected from: R 1 are each independently selected from H, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl and C 3-6 Cycloalkyl; X 1 , X 2 , X 3 Each independently selected from CR 9 and N; R 2 For LR 2 '; L is selected from a direct bond and -(CR 5 R 6 ) p -; R 2 'Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 2-6 Heteroalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl and 5-10 membered heteroaryl, the alkyl, alkoxy, hydroxyalkyl, heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted with one or more halogen, -OH, -CN, -NR 7 R 8 , C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 Cycloalkyl, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl substituted; R 3 Selected from H and C 1-4 alkyl; R 4 is independently selected at each occurrence from H, -OH, halogen, -CN, -NR 7 R 8 、-NHCOCH3、C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Haloalkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, wherein the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, aryl, heteroaryl are optionally substituted with one or more halogen, -CN, -NR 5 R 6 , C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-8 cycloalkoxy, 3-6 membered heterocyclic group; or, R 3 , R 4 The atoms connected to it form a 3-8 membered heterocyclic group, a 5-8 membered cycloalkyl group, a C 6-10 Aromatic rings and 5-10 membered heteroaromatic rings; R 5 and R 6 Each independently selected from H, C 1-4 Alkyl and C 3-8 Cycloalkyl; R 7 and R 8 Each independently selected from H and C 1-4 alkyl; R 9 are each independently selected from H, halogen, C 1-4 Alkyl and C 1-4 Haloalkyl; m is 0, 1 or 2; n is 0, 1, 2 or 3; p is 1 or 2.
3. The compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein ring A is selected from phenyl and pyridyl.
4. The compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein R 1 Each independently selected from H and C 1-4 alkyl.
5. The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein R 2 'Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Heteroalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl and 5-10 membered heteroaryl, wherein the alkyl, alkoxy, heteroalkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-6 The alkyl radicals are substituted with cycloalkyl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl.
6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein R 2 'Independently selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, C 3-6 Cycloalkyl and 5-6 membered heteroaryl, wherein the alkyl, heteroalkyl, cycloalkyl, heteroaryl are optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, 3-6 membered cycloalkyl, 3-6 membered heterocyclic group.
7. The compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein R 2 ' is independently selected from methyl, pyrimidinyl, pyridinyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, Pyrazolyl and -CH2-O-CH3, the methyl, pyrimidinyl, pyridyl, cyclopropyl, cyclobutyl, cyclopentyl, pyrazolyl are optionally substituted by methyl, F.
8. The compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein R 4 is independently selected at each occurrence from H, halogen, CN, -NR 7 R 8 , C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Haloalkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, 5-10 membered heteroaryl, wherein the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkoxy, heteroaryl are optionally substituted with one or more halogen, CN, -NR 5 R 6 , C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-8 Cycloalkoxy or 3-6 membered heterocyclic group.
9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein R 4 Each occurrence is independently selected from C 1-4 Halogenated alkyl, C 1-4 haloalkoxy and 5-6 membered heteroaryl, the heteroaryl being optionally substituted by one or more halogen, C 1-4 Alkyl, C 1-4 Haloalkyl substitution.
10. The compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein R 7 and R 8 Each independently selected from H and C 1-4 alkyl.
11. A compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein the compound has a structure of Formula IA: in, Ring A, R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , m, n are as defined in any one of claims 1-10.
12. A compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein the compound has a structure of Formula IB: in, Ring A, R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , m, n are as defined in any one of claims 1-10.
13. The compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein: Ring A is selected from phenyl and pyridyl; R 1 Each independently selected from H and C 1-4 alkyl; R 2 For LR 2 '; L is selected from a direct bond or -(CR 5 R 6 ) p -; R 5 and R 6 Each independently selected from H and C 1-4 alkyl; R 2 'Independently selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, C 3-6 Cycloalkyl and 5-10 membered heteroaryl, wherein the alkyl, heteroalkyl, cycloalkyl, heteroaryl are optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Heterocyclyl substitution; R 3 Selected from H and C 1-4 alkyl; R 4 is independently selected at each occurrence from H, halogen, C 1-4 Haloalkyl, C 1-4 haloalkoxy, 5-10 membered heteroaryl, the heteroaryl being optionally substituted with one or more halogen, C 1-4 Alkyl, C 1-4 haloalkyl substituted; or, R 3 and R 4 Together they form a 3-8 membered heterocyclic ring; X 1 and X 2 Each independently selected from CR 9 and N; R 9 Selected from H, halogen, C 1-3 Alkyl and C 1-3 Haloalkyl; m is 0 or 1; n is 1 or 2; and p is 1.
14. The compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein: Formula I is further I-1 or I-2: Preferably, Formula I is further Formula IA-1 or IA-2: Preferably, Formula I is further Formula IA-1a, IA-1b, IA-2a or IA-2b: Here, q is 0, 1 or 2, preferably 1 or 2.
15. The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, which satisfies one or more of the following: (1) Ring A is selected from phenyl and pyridyl; preferably selected from phenyl; (2)R 1 Each independently is H; (3)X 1 and X 2 Each independently selected from CR 9 and N; preferably selected from CR 9 ; (4)R 2 'Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 2-6 Heteroalkyl, non-cyclopropyl C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl and non-pyrazolyl 5-10 membered heteroaryl, preferably selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 2-6 Heteroalkyl, 3-8 membered heterocyclic group, C 3-8 Cycloalkoxy, C 6-10 Aryl, or preferably selected from C 1-4 Alkyl, C 2-6 Heteroalkyl, non-cyclopropyl C 3-6 Cycloalkyl and non-pyrazolyl 5-10 membered heteroaryl, preferably selected from C 1-4 Alkyl, C 2-6 heteroalkyl, cyclobutyl, cyclopentyl, Pyrimidinyl, pyridinyl, preferably selected from C 1-4 Alkyl, C 2-6 heteroalkyl, wherein the alkyl, alkoxy, hydroxyalkyl, heteroalkyl, cycloalkyl, heterocyclyl, cycloalkyloxy, aryl, heteroaryl are optionally substituted with one or more halogen, -OH, -CN, -NR 7 R 8 , C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic group, C 6-10 Aryl substitution; (5)R 4 is independently selected at each occurrence from H, -OH, halogen, -CN, -NR 7 R 8 、-NHCOCH3、C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Haloalkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl and non-pyrazolyl 5-10 membered heteroaryl, preferably selected from H, -OH, halogen, -CN, -NR 7 R 8 、-NHCOCH3、C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Haloalkoxy, C 3-8 Cycloalkyl, C 3-8 Cycloalkoxy, 3-8 membered heterocyclic group, C 6-10 Aryl, preferably selected from H, halogen, CN, -NR 7 R 8 , C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 2-6 Heteroalkyl, C 1-4 Haloalkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, preferably selected from H, halogen, C 1-4 Haloalkyl, C 1-4 Halogenated alkoxy, non-pyrazolyl 5-10 membered heteroaryl, preferably selected from C 1-4 Haloalkyl and C 1-4 Halogenated alkoxy, preferably selected from C 1-4 haloalkyl, wherein the heteroalkyl, cycloalkyl, heterocyclyl, cycloalkyloxy, aryl, heteroaryl are optionally substituted with one or more halogen, -CN, -NR 5 R 6 , C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-8 Cycloalkoxy, 3-6 membered heterocyclic substitution; (6)R 5 and R 6 Each independently selected from H, C 1-4 alkyl; (7)R 9 are each independently selected from halogen, C 1-4 Alkyl and C 1-4 Haloalkyl, preferably selected from halogen, preferably selected from F; (8) m is 0 or 1, preferably 0; (9) n is 0, 1 or 2, preferably 1 or 2; (10)p is 1.
16. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, which satisfies one or more of the following: (1)X 1 and X 2 Each independently selected from CR 9 ; (2)R 2 'Independently selected from C 1-4 Alkyl, C 2-6 heteroalkyl, cyclobutyl, cyclopentyl, Pyrimidinyl, pyridinyl, the alkyl, heteroalkyl, pyrimidinyl, pyridinyl, cyclobutyl, cyclopentyl are optionally substituted by C 1-4 Alkyl or halogen substituted; (3)R 4 Each occurrence is independently selected from C 1-4 Haloalkyl and C 1-4 Haloalkoxy; (4)R 9 are each independently selected from halogen.
17. The compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, wherein: The compound is:
18. A pharmaceutical composition comprising the compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, and one or more pharmaceutically acceptable carriers.
19. Use of a compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotope-labeled compound thereof, or a pharmaceutical composition according to claim 18 in the preparation of a medicament for preventing or treating a disease or condition associated with PRMT5 activity.
20. The use according to claim 19, wherein The disease or condition associated with PRMT5 activity is a cancer or tumor in which MTAP is deficient, preferably, the cancer or tumor is selected from esophageal cancer, lung cancer, pancreatic cancer, glioblastoma, bile duct cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular carcinoma, prostate cancer, melanoma, gastric cancer, colon cancer, leukemia (B-CLL) and lymphoma.
Citation Information
Patent Citations
PRMT5 inhibitor and application thereof
CN117362323A
Tricyclic carboxamide derivatives as PRMT5 inhibitors
WO2022115377A1
Tricyclic-amido-bicyclic PRMT5 inhibitors
WO2022169948A1
Amino-substituted heteroaryl derivatives and use thereof
WO2023246873A1
PRMT5 inhibitors and use thereof
WO2024002376A1
Cited By
PRMT5 inhibitors and uses thereof
US12448388B2
PRMT5 inhibitors and uses thereof
US12799113B2
